<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Bull World Health Organ</journal-id><journal-id journal-id-type="iso-abbrev">Bull. World Health Organ</journal-id><journal-id journal-id-type="publisher-id">BLT</journal-id><journal-title-group><journal-title>Bulletin of the World Health Organization</journal-title></journal-title-group><issn pub-type="ppub">0042-9686</issn><issn pub-type="epub">1564-0604</issn><publisher><publisher-name>World Health Organization</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28250534</article-id><article-id pub-id-type="pmc">5328107</article-id><article-id pub-id-type="publisher-id">BLT.16.173039</article-id><article-id pub-id-type="doi">10.2471/BLT.16.173039</article-id><article-categories><subj-group subj-group-type="heading"><subject>Systematic Reviews</subject></subj-group></article-categories><title-group><article-title>Pre-exposure rabies prophylaxis: a systematic review</article-title><trans-title-group xml:lang="fr"><trans-title xml:lang="fr">Prophylaxie pr&#x000e9;-exposition &#x000e0; la rage: un examen syst&#x000e9;matique</trans-title></trans-title-group><trans-title-group xml:lang="es"><trans-title xml:lang="es">Profilaxis pre exposici&#x000f3;n a la rabia: una revisi&#x000f3;n sistem&#x000e1;tica</trans-title></trans-title-group><trans-title-group xml:lang="ar"><trans-title xml:lang="ar">&#x00627;&#x00644;&#x00648;&#x00642;&#x00627;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00637;&#x00628;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00633;&#x00627;&#x00628;&#x00642;&#x00629; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00639;&#x00631;&#x00636; &#x00644;&#x0062f;&#x00627;&#x00621; &#x00627;&#x00644;&#x00633;&#x0064f;&#x00639;&#x00627;&#x00631;: &#x00645;&#x00631;&#x00627;&#x0062c;&#x00639;&#x00629; &#x00645;&#x00646;&#x00647;&#x0062c;&#x0064a;&#x00629; </trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title xml:lang="zh">&#x072c2;&#x072ac;&#x075c5;&#x066b4;&#x09732;&#x0524d;&#x09884;&#x09632;&#x0ff1a; &#x07cfb;&#x07edf;&#x05ba1;&#x067e5;</trans-title></trans-title-group><trans-title-group xml:lang="ru"><trans-title xml:lang="ru">&#x00414;&#x0043e;&#x0043a;&#x0043e;&#x0043d;&#x00442;&#x00430;&#x0043a;&#x00442;&#x0043d;&#x00430;&#x0044f; &#x0043f;&#x00440;&#x0043e;&#x00444;&#x00438;&#x0043b;&#x00430;&#x0043a;&#x00442;&#x00438;&#x0043a;&#x00430; &#x00431;&#x00435;&#x00448;&#x00435;&#x0043d;&#x00441;&#x00442;&#x00432;&#x00430;: &#x00441;&#x00438;&#x00441;&#x00442;&#x00435;&#x0043c;&#x00430;&#x00442;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438;&#x00439; &#x0043e;&#x00431;&#x00437;&#x0043e;&#x00440;</trans-title></trans-title-group><alt-title alt-title-type="author-running-head">Jocelyn A Kessels et al.</alt-title><alt-title alt-title-type="title-running-head">Pre-exposure rabies prophylaxis</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Kessels</surname><given-names>Jocelyn A</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Recuenco</surname><given-names>Sergio</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Navarro-Vela</surname><given-names>Ana Maria</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Deray</surname><given-names>Raffy</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vigilato</surname><given-names>Marco</given-names></name><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ertl</surname><given-names>Hildegund</given-names></name><xref ref-type="aff" rid="aff6"><sup>f</sup></xref></contrib><contrib contrib-type="author"><name><surname>Durrheim</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff7"><sup>g</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rees</surname><given-names>Helen</given-names></name><xref ref-type="aff" rid="aff8"><sup>h</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nel</surname><given-names>Louis H</given-names></name><xref ref-type="aff" rid="aff9"><sup>i</sup></xref></contrib><contrib contrib-type="author"><name><surname>Abela-Ridder</surname><given-names>Bernadette</given-names></name><xref ref-type="aff" rid="aff10"><sup>j</sup></xref></contrib><contrib contrib-type="author"><name><surname>Briggs</surname><given-names>Deborah</given-names></name><xref ref-type="aff" rid="aff11"><sup>k</sup></xref></contrib><aff id="aff1"><label>a</label>School of Veterinary Science, University of Queensland Gatton Campus, Via Warrego Highway, Gatton, Queensland 4343, <country>Australia</country>.</aff><aff id="aff2"><label>b</label>National Centre for Public Health, Instituto Nacional de Salud, Lima, <country>Peru</country>.</aff><aff id="aff3"><label>c</label>Directorate General of Strategic Interventions in Public Health, Ministry of Health, Lima, <country>Peru</country>.</aff><aff id="aff4"><label>d</label>Diseases Prevention and Control Bureau, Department of Health, Manilla, <country>Philippines</country>.</aff><aff id="aff5"><label>e</label>Veterinary Public Health Unit, Pan American Health Organisation&#x02013;World Health Organisation, Rio de Janeiro, <country>Brazil</country>.</aff><aff id="aff6"><label>f</label>Wistar Institute Vaccine Center, Philadelphia, United States of America (USA).</aff><aff id="aff7"><label>g</label>Hunter Medical Research Institution, University of Newcastle, Newcastle, <country>Australia</country>.</aff><aff id="aff8"><label>h</label>Wits Reproductive Health and HIV Institute, University of Witwatersrand, Johannesburg, <country>South Africa</country>.</aff><aff id="aff9"><label>i</label>Department of Microbiology and Plant Pathology, University of Pretoria, Pretoria, <country>South Africa</country>.</aff><aff id="aff10"><label>j</label>Neglected Zoonotic Diseases, World Health Organization, Geneva, <country>Switzerland</country>.</aff><aff id="aff11"><label>k</label>College of Veterinary Medicine, Kansas State University, Manhattan, <country>USA</country>.</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to Jocelyn A Kessels (email: <email xlink:href="jocelyn.kessels@uq.net.au">jocelyn.kessels@uq.net.au</email>).</corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>25</day><month>11</month><year>2016</year></pub-date><volume>95</volume><issue>3</issue><fpage>210</fpage><lpage>219C</lpage><history><date date-type="received"><day>07</day><month>3</month><year>2016</year></date><date date-type="rev-recd"><day>15</day><month>9</month><year>2016</year></date><date date-type="accepted"><day>28</day><month>9</month><year>2016</year></date></history><permissions><copyright-statement>(c) 2017 The authors; licensee World Health Organization.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/igo/legalcode">http://creativecommons.org/licenses/by/3.0/igo/legalcode</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.</license-p></license></permissions><abstract><title>Abstract</title><sec><title>Objective</title><p>To review the safety and immunogenicity of pre-exposure rabies prophylaxis (including accelerated schedules, co-administration with other vaccines and booster doses), its cost&#x02013;effectiveness and recommendations for use, particularly in high-risk settings.</p></sec><sec><title>Methods</title><p>We searched the PubMed, Centre for Agriculture and Biosciences International, Cochrane Library and Web of Science databases for papers on pre-exposure rabies prophylaxis published between 2007 and 29 January 2016. We reviewed field data from pre-exposure prophylaxis campaigns in Peru and the Philippines.</p></sec><sec><title>Findings</title><p>Pre-exposure rabies prophylaxis was safe and immunogenic in children and adults, also when co-administered with routine childhood vaccinations and the Japanese encephalitis vaccine. The evidence available indicates that shorter regimens and regimens involving fewer doses are safe and immunogenic and that booster intervals could be extended up to 10&#x000a0;years. The few studies on cost suggest that, at current vaccine and delivery costs, pre-exposure prophylaxis campaigns would not be cost-effective in most situations. Although pre-exposure prophylaxis has been advocated for high-risk populations, only Peru and the Philippines have implemented appropriate national programmes. In the future, accelerated regimens and novel vaccines could simplify delivery and increase affordability.</p></sec><sec><title>Conclusion</title><p>Pre-exposure rabies prophylaxis is safe and immunogenic and should be considered: (i)&#x000a0;where access to postexposure prophylaxis is limited or delayed; (ii)&#x000a0;where the risk of exposure is high and may go unrecognized; and (iii)&#x000a0;where controlling rabies in the animal reservoir is difficult. Pre-exposure prophylaxis should not distract from canine vaccination efforts, provision of postexposure prophylaxis or education to increase rabies awareness in local communities.</p></sec></abstract><trans-abstract xml:lang="fr"><title>R&#x000e9;sum&#x000e9;</title><sec><title>Objectif</title><p>Analyser l'innocuit&#x000e9; et l'immunog&#x000e9;nicit&#x000e9; de la prophylaxie pr&#x000e9;-exposition &#x000e0; la rage (notamment le sch&#x000e9;ma de vaccination acc&#x000e9;l&#x000e9;r&#x000e9;, la co-administration d'autres vaccins et les injections de rappel), son rapport co&#x000fb;t-efficacit&#x000e9; ainsi que les recommandations d'utilisation, en particulier dans les zones &#x000e0; haut risque.</p></sec><sec><title>M&#x000e9;thodes</title><p>Nous avons recherch&#x000e9;, dans les bases de donn&#x000e9;es de PubMed, du Centre for Agriculture and Biosciences International, de la Cochrane Library et de Web of Science, des articles sur la prophylaxie pr&#x000e9;-exposition &#x000e0; la rage publi&#x000e9;s entre 2007 et le 29&#x000a0;janvier&#x000a0;2016. Nous avons aussi analys&#x000e9; des donn&#x000e9;es de terrain provenant de campagnes pour la prophylaxie pr&#x000e9;-exposition men&#x000e9;es au P&#x000e9;rou et aux Philippines.</p></sec><sec><title>R&#x000e9;sultats</title><p>La prophylaxie pr&#x000e9;-exposition &#x000e0; la rage &#x000e9;tait s&#x000fb;re et immunog&#x000e8;ne pour les enfants et les adultes, m&#x000ea;me co-administr&#x000e9;e avec les vaccins syst&#x000e9;matiques des enfants et le vaccin contre l'enc&#x000e9;phalite japonaise. Les &#x000e9;l&#x000e9;ments disponibles indiquent que les programmes de vaccination plus courts ainsi que ceux comportant des doses plus faibles sont s&#x000fb;rs et immunog&#x000e8;nes et que les intervalles de rappel pourraient aller jusqu'&#x000e0; 10&#x000a0;ans. Selon les rares &#x000e9;tudes sur les co&#x000fb;ts, en tenant compte du co&#x000fb;t actuel des vaccins et de leur administration, dans la plupart des cas, les campagnes pour la prophylaxie pr&#x000e9;-exposition ne seraient pas rentables. M&#x000ea;me s&#x02019;il a &#x000e9;t&#x000e9; recommand&#x000e9; d&#x02019;appliquer une prophylaxie pr&#x000e9;-exposition dans les populations &#x000e0; haut risque, seuls le P&#x000e9;rou et les Philippines ont mis en &#x00153;uvre des programmes nationaux &#x000e0; cet &#x000e9;gard. Dans l'avenir, des sch&#x000e9;mas de vaccination acc&#x000e9;l&#x000e9;r&#x000e9;s et de nouveaux vaccins pourraient en simplifier l'administration, &#x000e0; des prix plus abordables.</p></sec><sec><title>Conclusion</title><p>La prophylaxie pr&#x000e9;-exposition &#x000e0; la rage est s&#x000fb;re et immunog&#x000e8;ne et devrait &#x000ea;tre envisag&#x000e9;e: (i)&#x000a0;lorsque l'acc&#x000e8;s &#x000e0; la prophylaxie post-exposition est limit&#x000e9; ou tardif; (ii)&#x000a0;lorsque le risque d'exposition est &#x000e9;lev&#x000e9; et pourrait passer inaper&#x000e7;u; et (iii)&#x000a0;lorsqu'il est difficile de lutter contre la rage dans le r&#x000e9;servoir animal. La prophylaxie pr&#x000e9;-exposition ne doit pas emp&#x000ea;cher les efforts de vaccination des chiens, la prophylaxie post-exposition ou la sensibilisation &#x000e0; la pr&#x000e9;vention de la rage dans les communaut&#x000e9;s locales.</p></sec></trans-abstract><trans-abstract xml:lang="es"><title>Resumen</title><sec><title>Objetivo</title><p>Analizar la seguridad y la inmunogenicidad de la profilaxis pre exposici&#x000f3;n a la rabia (incluidos programas acelerados, administraci&#x000f3;n conjunta con otras vacunas y dosis de refuerzo), su rentabilidad y las recomendaciones de uso, especialmente en entornos de alto riesgo.</p></sec><sec><title>M&#x000e9;todos</title><p>Se realizaron b&#x000fa;squedas en PubMed, el Centro Internacional de Agricultura y Ciencias Biol&#x000f3;gicas, la Biblioteca Cochrane y la base de datos de la Web of Science en busca de documentos sobre la profilaxis pre exposici&#x000f3;n a la rabia publicados entre 2007 y el 29 de enero de 2016. Se analizaron datos archivados de campa&#x000f1;as de profilaxis pre exposici&#x000f3;n en Filipinas y Per&#x000fa;.</p></sec><sec><title>Resultados</title><p>La profilaxis pre exposici&#x000f3;n a la rabia era segura e inmunog&#x000e9;nica en ni&#x000f1;os y adultos, tambi&#x000e9;n cuando se administraba en conjunto con vacunas infantiles rutinarias y la vacuna de la encefalitis japonesa. Las pruebas disponibles indican que los reg&#x000ed;menes m&#x000e1;s cortos y los que implican un menor n&#x000fa;mero de dosis son seguros e inmunog&#x000e9;nicos, y que los intervalos de refuerzo podr&#x000ed;an ampliarse hasta 10 a&#x000f1;os. Los pocos estudios sobre el coste sugieren que, con los costes actuales de vacunaci&#x000f3;n y suministro, las campa&#x000f1;as de profilaxis pre exposici&#x000f3;n no ser&#x000ed;an rentables en la mayor&#x000ed;a de las situaciones. A pesar de que la profilaxis pre exposici&#x000f3;n est&#x000e1; destinada para poblaciones de alto riesgo, &#x000fa;nicamente Filipinas y Per&#x000fa; han implementado los programas nacionales adecuados. En el futuro, los reg&#x000ed;menes acelerados y las nuevas vacunas podr&#x000ed;an simplificar el suministro y aumentar la asequibilidad.</p></sec><sec><title>Conclusi&#x000f3;n</title><p>La profilaxis pre exposici&#x000f3;n a la rabia es segura e inmunog&#x000e9;nica y debe tenerse en cuenta: (i) cuando el acceso a la profilaxis post exposici&#x000f3;n sea limitada o se retrase; (ii) cuando el riesgo de exposici&#x000f3;n sea alto y pueda pasar desapercibido; y (iii) cuando sea complicado controlar la rabia en una reserva animal. La profilaxis pre exposici&#x000f3;n no debe apartar la atenci&#x000f3;n de las vacunas caninas, el suministro de profilaxis post exposici&#x000f3;n o la educaci&#x000f3;n para aumentar la concienciaci&#x000f3;n sobre la rabia en comunidades locales.</p></sec></trans-abstract><trans-abstract xml:lang="ar"><title>&#x00645;&#x00644;&#x0062e;&#x00635; </title><sec><title>&#x00627;&#x00644;&#x0063a;&#x00631;&#x00636; </title><p>&#x00645;&#x00631;&#x00627;&#x0062c;&#x00639;&#x00629; &#x00639;&#x00648;&#x00627;&#x00645;&#x00644; &#x00627;&#x00644;&#x00623;&#x00645;&#x00627;&#x00646; &#x00648;&#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00645;&#x00646;&#x00627;&#x00639; &#x00627;&#x00644;&#x00642;&#x00631;&#x0064a;&#x00646;&#x00629; &#x00628;&#x00625;&#x0062c;&#x00631;&#x00627;&#x00621;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00648;&#x00642;&#x00627;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00637;&#x00628;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00633;&#x00627;&#x00628;&#x00642;&#x00629; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00639;&#x00631;&#x00636; &#x00644;&#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x00633;&#x0064f;&#x00639;&#x00627;&#x00631; (&#x0062f;&#x00627;&#x00621; &#x00627;&#x00644;&#x00643;&#x00644;&#x00628;) (&#x00628;&#x00645;&#x00627; &#x0064a;&#x00634;&#x00645;&#x00644; &#x00627;&#x00644;&#x0062c;&#x0062f;&#x00627;&#x00648;&#x00644; &#x00627;&#x00644;&#x00632;&#x00645;&#x00646;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x00639;&#x0062c;&#x00651;&#x00644;&#x00629;&#x0060c; &#x00648;&#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00645; &#x00627;&#x00644;&#x00623;&#x0062f;&#x00648;&#x0064a;&#x00629; &#x00645;&#x00639; &#x0063a;&#x0064a;&#x00631;&#x00647;&#x00627; &#x00645;&#x00646; &#x00627;&#x00644;&#x0062a;&#x0062d;&#x00635;&#x0064a;&#x00646;&#x00627;&#x0062a; &#x00648;&#x00627;&#x00644;&#x0062c;&#x00631;&#x00639;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00645;&#x00646;&#x00634;&#x00637;&#x00629;)&#x0060c; &#x00648;&#x00641;&#x00639;&#x00627;&#x00644;&#x0064a;&#x00629; &#x00627;&#x00644;&#x0062a;&#x00643;&#x00644;&#x00641;&#x00629; &#x00648;&#x00627;&#x00644;&#x0062a;&#x00648;&#x00635;&#x0064a;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062e;&#x00627;&#x00635;&#x00629; &#x00628;&#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00639;&#x00645;&#x00627;&#x00644;&#x0060c; &#x00648;&#x0062e;&#x00627;&#x00635;&#x00629;&#x0064b; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00628;&#x0064a;&#x00626;&#x00627;&#x0062a; &#x00639;&#x00627;&#x00644;&#x0064a;&#x00629; &#x00627;&#x00644;&#x0062e;&#x00637;&#x00648;&#x00631;&#x00629;. </p></sec><sec><title>&#x00627;&#x00644;&#x00637;&#x00631;&#x0064a;&#x00642;&#x00629; </title><p>&#x00642;&#x00645;&#x00646;&#x00627; &#x00628;&#x00627;&#x00644;&#x00628;&#x0062d;&#x0062b; &#x00641;&#x0064a; &#x00642;&#x00648;&#x00627;&#x00639;&#x0062f; &#x00628;&#x0064a;&#x00627;&#x00646;&#x00627;&#x0062a; PubMed&#x0060c; &#x00648;&#x00627;&#x00644;&#x00645;&#x00631;&#x00643;&#x00632; &#x00627;&#x00644;&#x0062f;&#x00648;&#x00644;&#x0064a; &#x00644;&#x00644;&#x00632;&#x00631;&#x00627;&#x00639;&#x00629; &#x00648;&#x00627;&#x00644;&#x00639;&#x00644;&#x00648;&#x00645; &#x00627;&#x00644;&#x0062d;&#x0064a;&#x00648;&#x0064a;&#x00629;&#x0060c; &#x00648;&#x00645;&#x00643;&#x0062a;&#x00628;&#x00629; Cochrane &#x00648;&#x00634;&#x00628;&#x00643;&#x00629; &#x00627;&#x00644;&#x00639;&#x00644;&#x00648;&#x00645; &#x00644;&#x00625;&#x0064a;&#x0062c;&#x00627;&#x0062f; &#x0062f;&#x00631;&#x00627;&#x00633;&#x00627;&#x0062a; &#x0062a;&#x0062a;&#x00639;&#x00644;&#x00642; &#x00628;&#x00625;&#x0062c;&#x00631;&#x00627;&#x00621;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00648;&#x00642;&#x00627;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00637;&#x00628;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00633;&#x00627;&#x00628;&#x00642;&#x00629; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00639;&#x00631;&#x00636; &#x00644;&#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x00633;&#x0064f;&#x00639;&#x00627;&#x00631; &#x00648;&#x00627;&#x00644;&#x0062a;&#x0064a; &#x0064a;&#x00639;&#x00648;&#x0062f; &#x0062a;&#x00627;&#x00631;&#x0064a;&#x0062e; &#x00646;&#x00634;&#x00631;&#x00647;&#x00627; &#x00625;&#x00644;&#x00649; &#x00627;&#x00644;&#x00641;&#x0062a;&#x00631;&#x00629; &#x00645;&#x00627; &#x00628;&#x0064a;&#x00646; 2007 &#x00648;29 &#x00643;&#x00627;&#x00646;&#x00648;&#x00646; &#x00627;&#x00644;&#x0062b;&#x00627;&#x00646;&#x0064a;/&#x0064a;&#x00646;&#x00627;&#x0064a;&#x00631; 2016. &#x00648;&#x00642;&#x00645;&#x00646;&#x00627; &#x00628;&#x00645;&#x00631;&#x00627;&#x0062c;&#x00639;&#x00629; &#x00627;&#x00644;&#x00628;&#x0064a;&#x00627;&#x00646;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00645;&#x0064a;&#x0062f;&#x00627;&#x00646;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x00623;&#x0062e;&#x00648;&#x00630;&#x00629; &#x00645;&#x00646; &#x0062d;&#x00645;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00648;&#x00642;&#x00627;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00637;&#x00628;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00633;&#x00627;&#x00628;&#x00642;&#x00629; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00639;&#x00631;&#x00636; &#x00644;&#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x00633;&#x0064f;&#x00639;&#x00627;&#x00631; &#x00627;&#x00644;&#x0062a;&#x0064a; &#x0062a;&#x00645;&#x0062a; &#x00641;&#x0064a; &#x00628;&#x0064a;&#x00631;&#x00648; &#x00648;&#x00627;&#x00644;&#x00641;&#x00644;&#x00628;&#x0064a;&#x00646;. </p></sec><sec><title>&#x00627;&#x00644;&#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; </title><p>&#x00643;&#x00627;&#x00646;&#x0062a; &#x00627;&#x00644;&#x00648;&#x00642;&#x00627;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00637;&#x00628;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00633;&#x00627;&#x00628;&#x00642;&#x00629; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00639;&#x00631;&#x00636; &#x00644;&#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x00633;&#x0064f;&#x00639;&#x00627;&#x00631; &#x0062a;&#x00631;&#x00627;&#x00639;&#x0064a; &#x00639;&#x00648;&#x00627;&#x00645;&#x00644; &#x00627;&#x00644;&#x00623;&#x00645;&#x00627;&#x00646; &#x00648;&#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00645;&#x00646;&#x00627;&#x00639; &#x00644;&#x0062f;&#x00649; &#x00627;&#x00644;&#x00623;&#x00637;&#x00641;&#x00627;&#x00644; &#x00648;&#x00627;&#x00644;&#x00643;&#x00628;&#x00627;&#x00631;&#x0060c; &#x00648;&#x00639;&#x00646;&#x0062f; &#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00645;&#x00647;&#x00627; &#x00645;&#x00639; &#x00627;&#x00644;&#x0062a;&#x0062d;&#x00635;&#x0064a;&#x00646;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00631;&#x00648;&#x0062a;&#x0064a;&#x00646;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x00642;&#x0062f;&#x00645;&#x00629; &#x00641;&#x0064a; &#x00645;&#x00631;&#x0062d;&#x00644;&#x00629; &#x00627;&#x00644;&#x00637;&#x00641;&#x00648;&#x00644;&#x00629; &#x00648;&#x00645;&#x00639; &#x0062a;&#x0062d;&#x00635;&#x0064a;&#x00646; &#x00627;&#x00644;&#x0062a;&#x00647;&#x00627;&#x00628; &#x00627;&#x00644;&#x0062f;&#x00645;&#x00627;&#x0063a; &#x00627;&#x00644;&#x0064a;&#x00627;&#x00628;&#x00627;&#x00646;&#x0064a;. &#x00648;&#x0062a;&#x00634;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00623;&#x0062f;&#x00644;&#x00629; &#x00627;&#x00644;&#x00645;&#x0062a;&#x00648;&#x00641;&#x00631;&#x00629; &#x00625;&#x00644;&#x00649; &#x00623;&#x00646; &#x00627;&#x00644;&#x00628;&#x00631;&#x00627;&#x00645;&#x0062c; &#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00623;&#x00642;&#x00635;&#x00631; &#x00648;&#x00627;&#x00644;&#x00628;&#x00631;&#x00627;&#x00645;&#x0062c; &#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c;&#x0064a;&#x00629; &#x00627;&#x00644;&#x0062a;&#x0064a; &#x0062a;&#x00639;&#x0062a;&#x00645;&#x0062f; &#x00639;&#x00644;&#x00649; &#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00645; &#x0062c;&#x00631;&#x00639;&#x00627;&#x0062a; &#x00623;&#x00642;&#x00644; &#x0062a;&#x00631;&#x00627;&#x00639;&#x0064a; &#x00639;&#x00648;&#x00627;&#x00645;&#x00644; &#x00627;&#x00644;&#x00623;&#x00645;&#x00627;&#x00646; &#x00648;&#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00645;&#x00646;&#x00627;&#x00639;&#x0060c; &#x00648;&#x00643;&#x00627;&#x00646; &#x00645;&#x00646; &#x00627;&#x00644;&#x00645;&#x00645;&#x00643;&#x00646; &#x00625;&#x00637;&#x00627;&#x00644;&#x00629; &#x00627;&#x00644;&#x00641;&#x0062a;&#x00631;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00632;&#x00645;&#x00646;&#x0064a;&#x00629; &#x00645;&#x00627; &#x00628;&#x0064a;&#x00646; &#x00627;&#x00644;&#x0062c;&#x00631;&#x00639;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00645;&#x00646;&#x00634;&#x00637;&#x00629; &#x00625;&#x00644;&#x00649; &#x00645;&#x00627; &#x0064a;&#x00635;&#x00644; &#x00625;&#x00644;&#x00649; 10 &#x00633;&#x00646;&#x00648;&#x00627;&#x0062a;. &#x00648;&#x0062a;&#x00634;&#x0064a;&#x00631; &#x00627;&#x00644;&#x0062f;&#x00631;&#x00627;&#x00633;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00642;&#x00644;&#x0064a;&#x00644;&#x00629; &#x0062d;&#x00648;&#x00644; &#x00627;&#x00644;&#x0062a;&#x00643;&#x00644;&#x00641;&#x00629; &#x00625;&#x00644;&#x00649; &#x00623;&#x00646; &#x0062d;&#x00645;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00648;&#x00642;&#x00627;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00637;&#x00628;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00633;&#x00627;&#x00628;&#x00642;&#x00629; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00639;&#x00631;&#x00636; &#x00644;&#x00644;&#x00645;&#x00631;&#x00636; &#x00644;&#x00646; &#x0062a;&#x00643;&#x00648;&#x00646; &#x00630;&#x00627;&#x0062a; &#x0062a;&#x00643;&#x00644;&#x00641;&#x00629; &#x00641;&#x00639;&#x00627;&#x00644;&#x00629; &#x00641;&#x0064a; &#x00623;&#x0063a;&#x00644;&#x00628; &#x00627;&#x00644;&#x00645;&#x00648;&#x00627;&#x00642;&#x00641; &#x00628;&#x00627;&#x00644;&#x00646;&#x00638;&#x00631; &#x00625;&#x00644;&#x00649; &#x00627;&#x00644;&#x00646;&#x00641;&#x00642;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062d;&#x00627;&#x00644;&#x0064a;&#x00629; &#x00644;&#x00644;&#x0062a;&#x0062d;&#x00635;&#x0064a;&#x00646;&#x00627;&#x0062a; &#x00648;&#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00645;&#x00647;&#x00627;. &#x00648;&#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x00631;&#x0063a;&#x00645; &#x00645;&#x00646; &#x00627;&#x00644;&#x0062f;&#x00639;&#x00648;&#x00629; &#x00625;&#x00644;&#x00649; &#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00645; &#x00627;&#x00644;&#x00648;&#x00642;&#x00627;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00637;&#x00628;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00633;&#x00627;&#x00628;&#x00642;&#x00629; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00639;&#x00631;&#x00636; &#x00644;&#x00644;&#x00645;&#x00631;&#x00636; &#x00644;&#x00644;&#x00642;&#x00637;&#x00627;&#x00639;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00633;&#x00643;&#x00627;&#x00646;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x00639;&#x00631;&#x00636;&#x00629; &#x00644;&#x0062f;&#x00631;&#x0062c;&#x00629; &#x00639;&#x00627;&#x00644;&#x0064a;&#x00629; &#x00645;&#x00646; &#x00627;&#x00644;&#x0062e;&#x00637;&#x00648;&#x00631;&#x00629;&#x0060c; &#x00641;&#x00642;&#x0062f; &#x00627;&#x00642;&#x0062a;&#x00635;&#x00631; &#x00627;&#x00644;&#x00623;&#x00645;&#x00631; &#x00639;&#x00644;&#x00649; &#x00628;&#x0064a;&#x00631;&#x00648; &#x00648;&#x00627;&#x00644;&#x00641;&#x00644;&#x00628;&#x0064a;&#x00646; &#x00641;&#x0064a; &#x0062a;&#x00637;&#x00628;&#x0064a;&#x00642; &#x00627;&#x00644;&#x00628;&#x00631;&#x00627;&#x00645;&#x0062c; &#x00627;&#x00644;&#x00648;&#x00637;&#x00646;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x00644;&#x00627;&#x00626;&#x00645;&#x00629;. &#x00648;&#x0064a;&#x00645;&#x00643;&#x00646; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00645;&#x00633;&#x0062a;&#x00642;&#x00628;&#x00644; &#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00645; &#x00623;&#x00646;&#x00638;&#x00645;&#x00629; &#x00639;&#x00644;&#x00627;&#x0062c;&#x0064a;&#x00629; &#x00645;&#x00639;&#x0062c;&#x00644;&#x00629; &#x00648;&#x0062a;&#x0062d;&#x00635;&#x0064a;&#x00646;&#x00627;&#x0062a; &#x00645;&#x00633;&#x0062a;&#x0062c;&#x0062f;&#x00629; &#x00644;&#x0062a;&#x00628;&#x00633;&#x0064a;&#x00637; &#x00639;&#x00645;&#x00644;&#x0064a;&#x00629; &#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00645; &#x00627;&#x00644;&#x0062e;&#x0062f;&#x00645;&#x00629; &#x00648;&#x00631;&#x00641;&#x00639; &#x00645;&#x00633;&#x0062a;&#x00648;&#x00649; &#x00627;&#x00644;&#x00643;&#x00641;&#x00627;&#x00621;&#x00629; &#x00641;&#x0064a; &#x00627;&#x00644;&#x0062a;&#x00643;&#x00644;&#x00641;&#x00629;. </p></sec><sec><title>&#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00646;&#x0062a;&#x00627;&#x0062c; </title><p>&#x0062a;&#x00631;&#x00627;&#x00639;&#x0064a; &#x00627;&#x00644;&#x00648;&#x00642;&#x00627;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00633;&#x00627;&#x00628;&#x00642;&#x00629; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00639;&#x00631;&#x00636; &#x00644;&#x0062f;&#x00627;&#x00621; &#x00627;&#x00644;&#x00633;&#x0064f;&#x00639;&#x00627;&#x00631; &#x00639;&#x00648;&#x00627;&#x00645;&#x00644; &#x00627;&#x00644;&#x00623;&#x00645;&#x00627;&#x00646; &#x00648;&#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00645;&#x00646;&#x00627;&#x00639; &#x00648;&#x0064a;&#x0064f;&#x00646;&#x00635;&#x0062d; &#x00628;&#x00627;&#x00644;&#x00627;&#x00644;&#x0062a;&#x00641;&#x00627;&#x0062a; &#x00625;&#x00644;&#x0064a;&#x00647;&#x00627;: (&#x00627;) &#x00625;&#x00630;&#x00627; &#x00645;&#x00627; &#x0062a;&#x00639;&#x00630;&#x00631;&#x0062a; &#x00633;&#x00628;&#x00644; &#x00627;&#x00644;&#x0062d;&#x00635;&#x00648;&#x00644; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x00648;&#x00642;&#x00627;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c;&#x0064a;&#x00629; &#x00628;&#x00639;&#x0062f; &#x00627;&#x00644;&#x0062a;&#x00639;&#x00631;&#x00636; &#x00644;&#x00644;&#x00645;&#x00631;&#x00636; &#x00623;&#x00648; &#x0062a;&#x00623;&#x0062e;&#x00631;&#x0062a;&#x0060c; &#x00648;(&#x00628;) &#x00625;&#x00630;&#x00627; &#x00645;&#x00627; &#x00643;&#x00627;&#x00646;&#x0062a; &#x00645;&#x0062e;&#x00627;&#x00637;&#x00631; &#x00627;&#x00644;&#x0062a;&#x00639;&#x00631;&#x00636; &#x00639;&#x00627;&#x00644;&#x0064a;&#x00629; &#x00648;&#x00644;&#x00627; &#x0062a;&#x00644;&#x00642;&#x00649; &#x0062d;&#x00642;&#x00647;&#x00627; &#x00645;&#x00646; &#x00627;&#x00644;&#x00627;&#x00647;&#x0062a;&#x00645;&#x00627;&#x00645;&#x0060c; &#x00648;(&#x0062c;&#x00640;) &#x00625;&#x00630;&#x00627; &#x00645;&#x00627; &#x00627;&#x00633;&#x0062a;&#x00639;&#x00635;&#x0062a; &#x00627;&#x00644;&#x00633;&#x0064a;&#x00637;&#x00631;&#x00629; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x00633;&#x0064f;&#x00639;&#x00627;&#x00631; &#x00641;&#x0064a; &#x00645;&#x00644;&#x00627;&#x0062c;&#x00626; &#x00627;&#x00644;&#x0062d;&#x0064a;&#x00648;&#x00627;&#x00646;&#x00627;&#x0062a;. &#x00648;&#x00644;&#x00627; &#x0064a;&#x00646;&#x00628;&#x0063a;&#x0064a; &#x00644;&#x00644;&#x00648;&#x00642;&#x00627;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00633;&#x00627;&#x00628;&#x00642;&#x00629; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00639;&#x00631;&#x00636; &#x00644;&#x00644;&#x00645;&#x00631;&#x00636; &#x00623;&#x00646; &#x0062a;&#x00646;&#x0062a;&#x00642;&#x00635; &#x00645;&#x00646; &#x0062c;&#x00647;&#x00648;&#x0062f; &#x0062a;&#x0062d;&#x00635;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00643;&#x00644;&#x00627;&#x00628;&#x0060c; &#x00623;&#x00648; &#x00627;&#x00644;&#x00648;&#x00642;&#x00627;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00644;&#x00627;&#x0062d;&#x00642;&#x00629; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00639;&#x00631;&#x00636; &#x00644;&#x00647;&#x0060c; &#x00623;&#x00648; &#x00627;&#x00644;&#x0062a;&#x00648;&#x00639;&#x0064a;&#x00629; &#x00644;&#x00632;&#x0064a;&#x00627;&#x0062f;&#x00629; &#x00627;&#x00644;&#x00648;&#x00639;&#x0064a; &#x00628;&#x0062f;&#x00627;&#x00621; &#x00627;&#x00644;&#x00633;&#x0064f;&#x00639;&#x00627;&#x00631; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00645;&#x0062c;&#x0062a;&#x00645;&#x00639;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00645;&#x0062d;&#x00644;&#x0064a;&#x00629;. </p></sec></trans-abstract><trans-abstract xml:lang="zh"><title>&#x06458;&#x08981;</title><sec><title>&#x076ee;&#x07684;</title><p>&#x04e3a;&#x04e86;&#x05ba1;&#x067e5;&#x072c2;&#x072ac;&#x075c5;&#x066b4;&#x09732;&#x0524d;&#x09884;&#x09632;&#x0ff08;&#x05305;&#x062ec;&#x052a0;&#x0901f;&#x06cbb;&#x07597;&#x0ff0c;&#x04e0e;&#x05176;&#x04ed6;&#x075ab;&#x082d7;&#x08054;&#x05408;&#x065bd;&#x0836f;&#x053ca;&#x052a0;&#x05f3a;&#x05242;&#x091cf;&#x0ff09;&#x07684;&#x05b89;&#x05168;&#x06027;&#x04e0e;&#x0514d;&#x075ab;&#x0539f;&#x06027;&#x0ff0c;&#x04ee5;&#x053ca;&#x05176;&#x06210;&#x0672c;&#x06548;&#x076ca;&#x0548c;&#x053ef;&#x063a8;&#x08350;&#x04f7f;&#x07528;&#x06027;&#x0ff0c;&#x05c24;&#x05176;&#x0662f;&#x05728;&#x09ad8;&#x053d1;&#x05730;&#x0533a;&#x03002;</p></sec><sec><title>&#x065b9;&#x06cd5;</title><p>&#x06211;&#x04eec;&#x05728;&#x07f8e;&#x056fd;&#x056fd;&#x07acb;&#x0533b;&#x05b66;&#x056fe;&#x04e66;&#x09986; (PubMed)&#x03001;&#x056fd;&#x09645;&#x0519c;&#x04e1a;&#x0548c;&#x0751f;&#x07269;&#x07814;&#x07a76;&#x04e2d;&#x05fc3; (Centre for Agriculture and Biosciences International)&#x03001;&#x08003;&#x079d1;&#x084dd;&#x056fe;&#x04e66;&#x09986; (Cochrane Library) &#x04ee5;&#x053ca; Web of Science &#x06570;&#x0636e;&#x05e93;&#x04e2d;&#x067e5;&#x0627e;&#x04e86;&#x000a0;2007&#x000a0;&#x05e74;&#x081f3;&#x000a0;2016&#x000a0;&#x05e74;&#x000a0;1&#x000a0;&#x06708;&#x000a0;29&#x000a0;&#x065e5;&#x0671f;&#x095f4;&#x0520a;&#x053d1;&#x07684;&#x04e0e;&#x072c2;&#x072ac;&#x075c5;&#x066b4;&#x09732;&#x0524d;&#x09884;&#x09632;&#x076f8;&#x05173;&#x07684;&#x08bba;&#x06587;&#x03002;&#x06b64;&#x05916;&#x0ff0c;&#x06211;&#x04eec;&#x08fd8;&#x056de;&#x0987e;&#x04e86;&#x079d8;&#x09c81;&#x04e0e;&#x083f2;&#x05f8b;&#x05bbe;&#x066b4;&#x09732;&#x0524d;&#x09884;&#x09632;&#x08fd0;&#x052a8;&#x07684;&#x073b0;&#x0573a;&#x06570;&#x0636e;&#x03002;</p></sec><sec><title>&#x07ed3;&#x0679c;</title><p>&#x072c2;&#x072ac;&#x075c5;&#x066b4;&#x09732;&#x0524d;&#x09884;&#x09632;&#x05728;&#x0513f;&#x07ae5;&#x04e0e;&#x06210;&#x04eba;&#x04eba;&#x07fa4;&#x04e2d;&#x05177;&#x06709;&#x05b89;&#x05168;&#x06027;&#x0548c;&#x0514d;&#x075ab;&#x0539f;&#x06027;&#x0ff0c;&#x06b64;&#x05916;&#x05728;&#x04e0e;&#x05176;&#x04ed6;&#x0513f;&#x07ae5;&#x05e38;&#x089c4;&#x075ab;&#x082d7;&#x063a5;&#x079cd;&#x053ca;&#x06d41;&#x0884c;&#x06027;&#x04e59;&#x0578b;&#x08111;&#x0708e;&#x075ab;&#x082d7;&#x08054;&#x05408;&#x07528;&#x0836f;&#x065f6;&#x04e5f;&#x080fd;&#x053d1;&#x06325;&#x05176;&#x05b89;&#x05168;&#x06027;&#x04e0e;&#x0514d;&#x075ab;&#x0539f;&#x06027;&#x03002; &#x073b0;&#x06709;&#x08bc1;&#x0636e;&#x08868;&#x0660e;&#x077ed;&#x0671f;&#x053ca;&#x05c11;&#x05242;&#x091cf;&#x065b9;&#x06848;&#x05177;&#x06709;&#x05b89;&#x05168;&#x06027;&#x0548c;&#x0514d;&#x075ab;&#x0539f;&#x06027;&#x0ff0c;&#x05176;&#x052a0;&#x05f3a;&#x05242;&#x091cf;&#x095f4;&#x09694;&#x053ef;&#x05ef6;&#x0957f;&#x081f3;&#x000a0;10&#x000a0;&#x05e74;&#x03002; &#x05c11;&#x06570;&#x06210;&#x0672c;&#x07814;&#x07a76;&#x08868;&#x0660e;&#x0ff0c;&#x0591a;&#x06570;&#x060c5;&#x051b5;&#x04e0b;&#x0ff0c;&#x05f53;&#x0524d;&#x075ab;&#x082d7;&#x053ca;&#x05176;&#x0914d;&#x09001;&#x06210;&#x0672c;&#x04ee5;&#x053ca;&#x066b4;&#x09732;&#x0524d;&#x09884;&#x09632;&#x06d3b;&#x052a8;&#x07684;&#x06210;&#x0672c;&#x06548;&#x076ca;&#x04e0d;&#x09ad8;&#x03002; &#x05c3d;&#x07ba1;&#x065e9;&#x05df2;&#x063d0;&#x05021;&#x09488;&#x05bf9;&#x09ad8;&#x05371;&#x04eba;&#x07fa4;&#x091c7;&#x07528;&#x066b4;&#x09732;&#x0524d;&#x09884;&#x09632;&#x0ff0c;&#x04f46;&#x04ec5;&#x06709;&#x079d8;&#x09c81;&#x04e0e;&#x083f2;&#x05f8b;&#x05bbe;&#x05b9e;&#x065bd;&#x04e86;&#x09002;&#x05f53;&#x07684;&#x056fd;&#x05bb6;&#x09879;&#x076ee;&#x03002; &#x0672a;&#x06765;&#x0ff0c;&#x05feb;&#x0901f;&#x06cbb;&#x07597;&#x065b9;&#x06848;&#x053ca;&#x065b0;&#x0578b;&#x075ab;&#x082d7;&#x05c06;&#x06709;&#x053ef;&#x080fd;&#x07b80;&#x05316;&#x0914d;&#x09001;&#x06d41;&#x07a0b;&#x05e76;&#x063d0;&#x09ad8;&#x053ef;&#x0627f;&#x053d7;&#x06027;&#x03002;</p></sec><sec><title>&#x07ed3;&#x08bba;</title><p>&#x072c2;&#x072ac;&#x075c5;&#x066b4;&#x09732;&#x0524d;&#x09884;&#x09632;&#x05177;&#x06709;&#x05b89;&#x05168;&#x06027;&#x0548c;&#x0514d;&#x075ab;&#x0539f;&#x06027;&#x0ff0c;&#x05e94;&#x08003;&#x08651;&#x0ff1a; (i)&#x000a0;&#x066b4;&#x09732;&#x0540e;&#x09884;&#x09632;&#x053d7;&#x09650;&#x06216;&#x06ede;&#x0540e;&#x07684;&#x05730;&#x065b9;&#x0ff1b;(ii)&#x000a0;&#x066b4;&#x09732;&#x098ce;&#x09669;&#x09ad8;&#x04e14;&#x05c1a;&#x0672a;&#x053d1;&#x073b0;&#x07684;&#x05730;&#x065b9;&#x0ff1b;&#x04ee5;&#x053ca;&#x000a0;(iii)&#x000a0;&#x063a7;&#x05236;&#x072c2;&#x072ac;&#x075c5;&#x052a8;&#x07269;&#x05bbf;&#x04e3b;&#x056f0;&#x096be;&#x07684;&#x05730;&#x065b9;&#x03002; &#x066b4;&#x09732;&#x0524d;&#x09884;&#x09632;&#x04e0d;&#x05e94;&#x08f6c;&#x079fb;&#x072ac;&#x053ea;&#x075ab;&#x082d7;&#x07684;&#x063a5;&#x079cd;&#x05de5;&#x04f5c;&#x0ff0c;&#x06b64;&#x05916;&#x08fd8;&#x05e94;&#x063d0;&#x04f9b;&#x063a5;&#x089e6;&#x0540e;&#x09884;&#x09632;&#x06216;&#x06559;&#x080b2;&#x04ee5;&#x063d0;&#x09ad8;&#x05f53;&#x05730;&#x0793e;&#x0533a;&#x07684;&#x072c2;&#x072ac;&#x075c5;&#x0610f;&#x08bc6;&#x03002;</p></sec></trans-abstract><trans-abstract xml:lang="ru"><title>&#x00420;&#x00435;&#x00437;&#x0044e;&#x0043c;&#x00435;</title><sec><title>&#x00426;&#x00435;&#x0043b;&#x0044c;</title><p>&#x0041f;&#x00440;&#x0043e;&#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x00442;&#x0044c; &#x00431;&#x00435;&#x00437;&#x0043e;&#x0043f;&#x00430;&#x00441;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x00438; &#x00438;&#x0043c;&#x0043c;&#x00443;&#x0043d;&#x0043e;&#x00433;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x00434;&#x0043e;&#x0043a;&#x0043e;&#x0043d;&#x00442;&#x00430;&#x0043a;&#x00442;&#x0043d;&#x0043e;&#x00439; &#x0043f;&#x00440;&#x0043e;&#x00444;&#x00438;&#x0043b;&#x00430;&#x0043a;&#x00442;&#x00438;&#x0043a;&#x00438; &#x00431;&#x00435;&#x00448;&#x00435;&#x0043d;&#x00441;&#x00442;&#x00432;&#x00430;&#x000a0;(&#x00432; &#x00442;&#x0043e;&#x0043c; &#x00447;&#x00438;&#x00441;&#x0043b;&#x00435; &#x00443;&#x00441;&#x0043a;&#x0043e;&#x00440;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00439; &#x0043a;&#x00443;&#x00440;&#x00441; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00430;&#x00446;&#x00438;&#x00438;, &#x0043d;&#x00430;&#x00437;&#x0043d;&#x00430;&#x00447;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00441; &#x00434;&#x00440;&#x00443;&#x00433;&#x00438;&#x0043c;&#x00438; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00430;&#x0043c;&#x00438; &#x00438; &#x00440;&#x00435;&#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00430;&#x00446;&#x00438;&#x00438;), &#x00435;&#x00435; &#x0044d;&#x0043a;&#x0043e;&#x0043d;&#x0043e;&#x0043c;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00443;&#x0044e; &#x0044d;&#x00444;&#x00444;&#x00435;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x00438; &#x00440;&#x00435;&#x0043a;&#x0043e;&#x0043c;&#x00435;&#x0043d;&#x00434;&#x00430;&#x00446;&#x00438;&#x00438; &#x0043f;&#x0043e; &#x0043f;&#x00440;&#x00438;&#x0043c;&#x00435;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044e;, &#x0043e;&#x00441;&#x0043e;&#x00431;&#x00435;&#x0043d;&#x0043d;&#x0043e; &#x00432; &#x00443;&#x00441;&#x0043b;&#x0043e;&#x00432;&#x00438;&#x0044f;&#x00445; &#x00432;&#x0044b;&#x00441;&#x0043e;&#x0043a;&#x0043e;&#x00433;&#x0043e; &#x00440;&#x00438;&#x00441;&#x0043a;&#x00430;.</p></sec><sec><title>&#x0041c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x0044b;</title><p>&#x00410;&#x00432;&#x00442;&#x0043e;&#x00440;&#x0044b; &#x0043e;&#x00441;&#x00443;&#x00449;&#x00435;&#x00441;&#x00442;&#x00432;&#x00438;&#x0043b;&#x00438; &#x0043f;&#x0043e;&#x00438;&#x00441;&#x0043a; &#x00441;&#x00442;&#x00430;&#x00442;&#x00435;&#x00439; &#x0043f;&#x0043e; &#x00434;&#x0043e;&#x0043a;&#x0043e;&#x0043d;&#x00442;&#x00430;&#x0043a;&#x00442;&#x0043d;&#x0043e;&#x00439; &#x0043f;&#x00440;&#x0043e;&#x00444;&#x00438;&#x0043b;&#x00430;&#x0043a;&#x00442;&#x00438;&#x0043a;&#x00435; &#x00431;&#x00435;&#x00448;&#x00435;&#x0043d;&#x00441;&#x00442;&#x00432;&#x00430;, &#x0043e;&#x0043f;&#x00443;&#x00431;&#x0043b;&#x00438;&#x0043a;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x0043c;&#x00435;&#x00436;&#x00434;&#x00443; 2007&#x000a0;&#x00433;&#x0043e;&#x00434;&#x0043e;&#x0043c; &#x00438; 29&#x000a0;&#x0044f;&#x0043d;&#x00432;&#x00430;&#x00440;&#x0044f; 2016&#x000a0;&#x00433;&#x0043e;&#x00434;&#x00430;, &#x00432; &#x00431;&#x00430;&#x00437;&#x00430;&#x00445; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00445; PubMed, &#x0041c;&#x00435;&#x00436;&#x00434;&#x00443;&#x0043d;&#x00430;&#x00440;&#x0043e;&#x00434;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00446;&#x00435;&#x0043d;&#x00442;&#x00440;&#x00430; &#x0043f;&#x0043e; &#x00441;&#x00435;&#x0043b;&#x0044c;&#x00441;&#x0043a;&#x0043e;&#x0043c;&#x00443; &#x00445;&#x0043e;&#x00437;&#x0044f;&#x00439;&#x00441;&#x00442;&#x00432;&#x00443; &#x00438; &#x00431;&#x00438;&#x0043e;&#x0043b;&#x0043e;&#x00433;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438;&#x0043c; &#x0043d;&#x00430;&#x00443;&#x0043a;&#x00430;&#x0043c;&#x000a0;(CABI), &#x0041a;&#x0043e;&#x0043a;&#x00440;&#x00430;&#x0043d;&#x0043e;&#x00432;&#x00441;&#x0043a;&#x0043e;&#x00439; &#x00431;&#x00438;&#x00431;&#x0043b;&#x00438;&#x0043e;&#x00442;&#x00435;&#x0043a;&#x00438; &#x00438; Web of Science. &#x00410;&#x00432;&#x00442;&#x0043e;&#x00440;&#x0044b; &#x0043f;&#x00440;&#x0043e;&#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043b;&#x00438; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00435;, &#x0043f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00435; &#x00432; &#x00440;&#x00430;&#x00431;&#x0043e;&#x00447;&#x00438;&#x00445; &#x00443;&#x00441;&#x0043b;&#x0043e;&#x00432;&#x00438;&#x0044f;&#x00445; &#x00432; &#x00445;&#x0043e;&#x00434;&#x00435; &#x0043a;&#x00430;&#x0043c;&#x0043f;&#x00430;&#x0043d;&#x00438;&#x00439; &#x0043f;&#x0043e; &#x00434;&#x0043e;&#x0043a;&#x0043e;&#x0043d;&#x00442;&#x00430;&#x0043a;&#x00442;&#x0043d;&#x0043e;&#x00439; &#x0043f;&#x00440;&#x0043e;&#x00444;&#x00438;&#x0043b;&#x00430;&#x0043a;&#x00442;&#x00438;&#x0043a;&#x00435; &#x00431;&#x00435;&#x00448;&#x00435;&#x0043d;&#x00441;&#x00442;&#x00432;&#x00430; &#x00432; &#x0041f;&#x00435;&#x00440;&#x00443; &#x00438; &#x0043d;&#x00430; &#x00424;&#x00438;&#x0043b;&#x00438;&#x0043f;&#x0043f;&#x00438;&#x0043d;&#x00430;&#x00445;.</p></sec><sec><title>&#x00420;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0044b;</title><p>&#x00414;&#x0043e;&#x0043a;&#x0043e;&#x0043d;&#x00442;&#x00430;&#x0043a;&#x00442;&#x0043d;&#x00430;&#x0044f; &#x0043f;&#x00440;&#x0043e;&#x00444;&#x00438;&#x0043b;&#x00430;&#x0043a;&#x00442;&#x00438;&#x0043a;&#x00430; &#x00431;&#x00435;&#x00448;&#x00435;&#x0043d;&#x00441;&#x00442;&#x00432;&#x00430; &#x00431;&#x0044b;&#x0043b;&#x00430; &#x00431;&#x00435;&#x00437;&#x0043e;&#x0043f;&#x00430;&#x00441;&#x0043d;&#x0043e;&#x00439; &#x00438; &#x00441;&#x0043f;&#x0043e;&#x00441;&#x0043e;&#x00431;&#x0043d;&#x0043e;&#x00439; &#x00432;&#x0044b;&#x00437;&#x0044b;&#x00432;&#x00430;&#x00442;&#x0044c; &#x00438;&#x0043c;&#x0043c;&#x00443;&#x0043d;&#x0043d;&#x0044b;&#x00439; &#x0043e;&#x00442;&#x00432;&#x00435;&#x00442; &#x00443; &#x00434;&#x00435;&#x00442;&#x00435;&#x00439; &#x00438; &#x00432;&#x00437;&#x00440;&#x0043e;&#x00441;&#x0043b;&#x0044b;&#x00445;, &#x00432; &#x00442;&#x0043e;&#x0043c; &#x00447;&#x00438;&#x00441;&#x0043b;&#x00435; &#x00432; &#x00441;&#x0043e;&#x00447;&#x00435;&#x00442;&#x00430;&#x0043d;&#x00438;&#x00438; &#x00441; &#x0043f;&#x0043b;&#x00430;&#x0043d;&#x0043e;&#x00432;&#x0043e;&#x00439; &#x00438;&#x0043c;&#x0043c;&#x00443;&#x0043d;&#x00438;&#x00437;&#x00430;&#x00446;&#x00438;&#x00435;&#x00439; &#x00434;&#x00435;&#x00442;&#x00435;&#x00439; &#x00438; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00430;&#x00446;&#x00438;&#x00435;&#x00439; &#x0043f;&#x00440;&#x0043e;&#x00442;&#x00438;&#x00432; &#x0044f;&#x0043f;&#x0043e;&#x0043d;&#x00441;&#x0043a;&#x0043e;&#x00433;&#x0043e; &#x0044d;&#x0043d;&#x00446;&#x00435;&#x00444;&#x00430;&#x0043b;&#x00438;&#x00442;&#x00430;. &#x0041d;&#x00430; &#x0043e;&#x00441;&#x0043d;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00438; &#x00434;&#x0043e;&#x00441;&#x00442;&#x00443;&#x0043f;&#x0043d;&#x0044b;&#x00445; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x0043c;&#x0043e;&#x00436;&#x0043d;&#x0043e; &#x00441;&#x00434;&#x00435;&#x0043b;&#x00430;&#x00442;&#x0044c; &#x00432;&#x0044b;&#x00432;&#x0043e;&#x00434; &#x0043e; &#x00442;&#x0043e;&#x0043c;, &#x00447;&#x00442;&#x0043e; &#x00431;&#x0043e;&#x0043b;&#x00435;&#x00435; &#x0043a;&#x0043e;&#x00440;&#x0043e;&#x00442;&#x0043a;&#x00438;&#x00435; &#x0043a;&#x00443;&#x00440;&#x00441;&#x0044b; &#x00438; &#x0043a;&#x00443;&#x00440;&#x00441;&#x0044b; &#x00441; &#x00438;&#x00441;&#x0043f;&#x0043e;&#x0043b;&#x0044c;&#x00437;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00435;&#x0043c; &#x0043c;&#x00435;&#x0043d;&#x0044c;&#x00448;&#x00435;&#x00433;&#x0043e; &#x0043a;&#x0043e;&#x0043b;&#x00438;&#x00447;&#x00435;&#x00441;&#x00442;&#x00432;&#x00430; &#x00434;&#x0043e;&#x00437; &#x00431;&#x00435;&#x00437;&#x0043e;&#x0043f;&#x00430;&#x00441;&#x0043d;&#x0044b;, &#x00432;&#x0044b;&#x00437;&#x0044b;&#x00432;&#x00430;&#x0044e;&#x00442; &#x00438;&#x0043c;&#x0043c;&#x00443;&#x0043d;&#x0043d;&#x0044b;&#x00439; &#x0043e;&#x00442;&#x00432;&#x00435;&#x00442; &#x00438; &#x00438;&#x0043d;&#x00442;&#x00435;&#x00440;&#x00432;&#x00430;&#x0043b;&#x0044b; &#x00440;&#x00435;&#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00430;&#x00446;&#x00438;&#x00438; &#x0043c;&#x0043e;&#x00433;&#x00443;&#x00442; &#x00431;&#x0044b;&#x00442;&#x0044c; &#x00443;&#x00432;&#x00435;&#x0043b;&#x00438;&#x00447;&#x00435;&#x0043d;&#x0044b; &#x00434;&#x0043e; 10&#x000a0;&#x0043b;&#x00435;&#x00442;. &#x00421;&#x00443;&#x00434;&#x0044f; &#x0043f;&#x0043e; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x00430;&#x0043c; &#x0043d;&#x00435;&#x0043c;&#x0043d;&#x0043e;&#x00433;&#x0043e;&#x00447;&#x00438;&#x00441;&#x0043b;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;&#x0043e;&#x00432; &#x00440;&#x00430;&#x00441;&#x00445;&#x0043e;&#x00434;&#x0043e;&#x00432;, &#x0043f;&#x00440;&#x00438; &#x00442;&#x00435;&#x0043a;&#x00443;&#x00449;&#x00438;&#x00445; &#x00437;&#x00430;&#x00442;&#x00440;&#x00430;&#x00442;&#x00430;&#x00445; &#x0043d;&#x00430; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00430;&#x00446;&#x00438;&#x0044e; &#x0043f;&#x00440;&#x00438;&#x0043c;&#x00435;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00438;&#x0043c;&#x00435;&#x0044e;&#x00449;&#x00435;&#x00439;&#x00441;&#x0044f; &#x00432; &#x0043d;&#x00430;&#x00441;&#x00442;&#x0043e;&#x0044f;&#x00449;&#x00435;&#x00435; &#x00432;&#x00440;&#x00435;&#x0043c;&#x0044f; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x0044b; &#x00432; &#x0043a;&#x00430;&#x0043c;&#x0043f;&#x00430;&#x0043d;&#x00438;&#x0044f;&#x00445; &#x0043f;&#x0043e; &#x00434;&#x0043e;&#x0043a;&#x0043e;&#x0043d;&#x00442;&#x00430;&#x0043a;&#x00442;&#x0043d;&#x0043e;&#x00439; &#x0043f;&#x00440;&#x0043e;&#x00444;&#x00438;&#x0043b;&#x00430;&#x0043a;&#x00442;&#x00438;&#x0043a;&#x00435; &#x0043d;&#x00435; &#x00431;&#x0044b;&#x0043b;&#x0043e; &#x00431;&#x0044b; &#x0044d;&#x0043a;&#x0043e;&#x0043d;&#x0043e;&#x0043c;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438; &#x0044d;&#x00444;&#x00444;&#x00435;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0043e; &#x00432; &#x00431;&#x0043e;&#x0043b;&#x0044c;&#x00448;&#x00438;&#x0043d;&#x00441;&#x00442;&#x00432;&#x00435; &#x00441;&#x0043b;&#x00443;&#x00447;&#x00430;&#x00435;&#x00432;. &#x00425;&#x0043e;&#x00442;&#x0044f; &#x00434;&#x0043e;&#x0043a;&#x0043e;&#x0043d;&#x00442;&#x00430;&#x0043a;&#x00442;&#x0043d;&#x00430;&#x0044f; &#x0043f;&#x00440;&#x0043e;&#x00444;&#x00438;&#x0043b;&#x00430;&#x0043a;&#x00442;&#x00438;&#x0043a;&#x00430; &#x00440;&#x00435;&#x0043a;&#x0043e;&#x0043c;&#x00435;&#x0043d;&#x00434;&#x00443;&#x00435;&#x00442;&#x00441;&#x0044f; &#x00434;&#x0043b;&#x0044f; &#x00433;&#x00440;&#x00443;&#x0043f;&#x0043f; &#x0043d;&#x00430;&#x00441;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f;, &#x0043f;&#x0043e;&#x00434;&#x00432;&#x00435;&#x00440;&#x00433;&#x00430;&#x0044e;&#x00449;&#x00438;&#x00445;&#x00441;&#x0044f; &#x00432;&#x0044b;&#x00441;&#x0043e;&#x0043a;&#x0043e;&#x0043c;&#x00443; &#x00440;&#x00438;&#x00441;&#x0043a;&#x00443;, &#x00441;&#x0043e;&#x0043e;&#x00442;&#x00432;&#x00435;&#x00442;&#x00441;&#x00442;&#x00432;&#x00443;&#x0044e;&#x00449;&#x00438;&#x00435; &#x0043d;&#x00430;&#x00446;&#x00438;&#x0043e;&#x0043d;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00435; &#x0043f;&#x00440;&#x0043e;&#x00433;&#x00440;&#x00430;&#x0043c;&#x0043c;&#x0044b; &#x00431;&#x0044b;&#x0043b;&#x00438; &#x00432;&#x0043d;&#x00435;&#x00434;&#x00440;&#x00435;&#x0043d;&#x0044b; &#x00442;&#x0043e;&#x0043b;&#x0044c;&#x0043a;&#x0043e; &#x00432; &#x0041f;&#x00435;&#x00440;&#x00443; &#x00438; &#x0043d;&#x00430; &#x00424;&#x00438;&#x0043b;&#x00438;&#x0043f;&#x0043f;&#x00438;&#x0043d;&#x00430;&#x00445;. &#x00412; &#x00431;&#x00443;&#x00434;&#x00443;&#x00449;&#x00435;&#x0043c; &#x00443;&#x00441;&#x0043a;&#x0043e;&#x00440;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00435; &#x0043a;&#x00443;&#x00440;&#x00441;&#x0044b; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00438; &#x0043d;&#x0043e;&#x00432;&#x0044b;&#x00435; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x0044b;, &#x00432;&#x0043e;&#x00437;&#x0043c;&#x0043e;&#x00436;&#x0043d;&#x0043e;, &#x0043f;&#x0043e;&#x00437;&#x00432;&#x0043e;&#x0043b;&#x0044f;&#x00442; &#x00443;&#x0043f;&#x00440;&#x0043e;&#x00441;&#x00442;&#x00438;&#x00442;&#x0044c; &#x00432;&#x0044b;&#x0043f;&#x0043e;&#x0043b;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00430;&#x00446;&#x00438;&#x00438; &#x00438; &#x0043f;&#x0043e;&#x00432;&#x0044b;&#x00441;&#x00438;&#x00442;&#x0044c; &#x00435;&#x00435; &#x00446;&#x00435;&#x0043d;&#x0043e;&#x00432;&#x00443;&#x0044e; &#x00434;&#x0043e;&#x00441;&#x00442;&#x00443;&#x0043f;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0044c;.</p></sec><sec><title>&#x00412;&#x0044b;&#x00432;&#x0043e;&#x00434;</title><p>&#x00414;&#x0043e;&#x0043a;&#x0043e;&#x0043d;&#x00442;&#x00430;&#x0043a;&#x00442;&#x0043d;&#x00430;&#x0044f; &#x0043f;&#x00440;&#x0043e;&#x00444;&#x00438;&#x0043b;&#x00430;&#x0043a;&#x00442;&#x00438;&#x0043a;&#x00430; &#x00431;&#x00435;&#x00448;&#x00435;&#x0043d;&#x00441;&#x00442;&#x00432;&#x00430; &#x00431;&#x00435;&#x00437;&#x0043e;&#x0043f;&#x00430;&#x00441;&#x0043d;&#x00430;, &#x00441;&#x0043f;&#x0043e;&#x00441;&#x0043e;&#x00431;&#x0043d;&#x00430; &#x00432;&#x0044b;&#x00437;&#x00432;&#x00430;&#x00442;&#x0044c; &#x00438;&#x0043c;&#x0043c;&#x00443;&#x0043d;&#x0043d;&#x0044b;&#x00439; &#x0043e;&#x00442;&#x00432;&#x00435;&#x00442; &#x00438; &#x00434;&#x0043e;&#x0043b;&#x00436;&#x0043d;&#x00430; &#x00431;&#x0044b;&#x00442;&#x0044c; &#x00440;&#x00435;&#x0043a;&#x0043e;&#x0043c;&#x00435;&#x0043d;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00430;: 1)&#x000a0;&#x0043a;&#x0043e;&#x00433;&#x00434;&#x00430; &#x00434;&#x0043e;&#x00441;&#x00442;&#x00443;&#x0043f; &#x0043a; &#x0043f;&#x0043e;&#x00441;&#x00442;&#x0043a;&#x0043e;&#x0043d;&#x00442;&#x00430;&#x0043a;&#x00442;&#x0043d;&#x0043e;&#x00439; &#x0043f;&#x00440;&#x0043e;&#x00444;&#x00438;&#x0043b;&#x00430;&#x0043a;&#x00442;&#x00438;&#x0043a;&#x00435; &#x0043e;&#x00433;&#x00440;&#x00430;&#x0043d;&#x00438;&#x00447;&#x00435;&#x0043d; &#x00438;&#x0043b;&#x00438; &#x0043f;&#x00440;&#x00435;&#x00434;&#x0043e;&#x00441;&#x00442;&#x00430;&#x00432;&#x0043b;&#x0044f;&#x00435;&#x00442;&#x00441;&#x0044f; &#x0043d;&#x00435;&#x00441;&#x00432;&#x0043e;&#x00435;&#x00432;&#x00440;&#x00435;&#x0043c;&#x00435;&#x0043d;&#x0043d;&#x0043e;; 2)&#x000a0;&#x0043a;&#x0043e;&#x00433;&#x00434;&#x00430; &#x00440;&#x00438;&#x00441;&#x0043a; &#x00437;&#x00430;&#x00440;&#x00430;&#x00436;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00432;&#x00435;&#x0043b;&#x00438;&#x0043a; &#x00438;&#x0043b;&#x00438; &#x0043c;&#x0043e;&#x00436;&#x00435;&#x00442; &#x00431;&#x0044b;&#x00442;&#x0044c; &#x0043d;&#x00435; &#x00440;&#x00430;&#x00441;&#x0043f;&#x0043e;&#x00437;&#x0043d;&#x00430;&#x0043d;; 3)&#x000a0;&#x0043a;&#x0043e;&#x00433;&#x00434;&#x00430; &#x00431;&#x0043e;&#x00440;&#x0044c;&#x00431;&#x00430; &#x00441; &#x00431;&#x00435;&#x00448;&#x00435;&#x0043d;&#x00441;&#x00442;&#x00432;&#x0043e;&#x0043c; &#x00443; &#x00436;&#x00438;&#x00432;&#x0043e;&#x00442;&#x0043d;&#x0044b;&#x00445;-&#x0043d;&#x0043e;&#x00441;&#x00438;&#x00442;&#x00435;&#x0043b;&#x00435;&#x00439; &#x00437;&#x00430;&#x00442;&#x00440;&#x00443;&#x00434;&#x0043d;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x00430;. &#x00414;&#x0043e;&#x0043a;&#x0043e;&#x0043d;&#x00442;&#x00430;&#x0043a;&#x00442;&#x0043d;&#x00430;&#x0044f; &#x0043f;&#x00440;&#x0043e;&#x00444;&#x00438;&#x0043b;&#x00430;&#x0043a;&#x00442;&#x00438;&#x0043a;&#x00430; &#x00431;&#x00435;&#x00448;&#x00435;&#x0043d;&#x00441;&#x00442;&#x00432;&#x00430; &#x0043d;&#x00435; &#x00434;&#x0043e;&#x0043b;&#x00436;&#x0043d;&#x00430; &#x00431;&#x0044b;&#x00442;&#x0044c; &#x0043f;&#x0043e;&#x00432;&#x0043e;&#x00434;&#x0043e;&#x0043c; &#x00434;&#x0043b;&#x0044f; &#x0043e;&#x00442;&#x0043a;&#x00430;&#x00437;&#x00430; &#x0043e;&#x00442; &#x0043c;&#x00435;&#x00440;&#x0043e;&#x0043f;&#x00440;&#x00438;&#x0044f;&#x00442;&#x00438;&#x00439; &#x0043f;&#x0043e; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00430;&#x00446;&#x00438;&#x00438; &#x00441;&#x0043e;&#x00431;&#x00430;&#x0043a;, &#x0043f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043f;&#x0043e;&#x00441;&#x00442;&#x0043a;&#x0043e;&#x0043d;&#x00442;&#x00430;&#x0043a;&#x00442;&#x0043d;&#x0043e;&#x00439; &#x0043f;&#x00440;&#x0043e;&#x00444;&#x00438;&#x0043b;&#x00430;&#x0043a;&#x00442;&#x00438;&#x0043a;&#x00438; &#x00438;&#x0043b;&#x00438; &#x00438;&#x0043d;&#x00444;&#x0043e;&#x00440;&#x0043c;&#x00430;&#x00446;&#x00438;&#x0043e;&#x0043d;&#x0043d;&#x0043e;-&#x0043f;&#x00440;&#x0043e;&#x00441;&#x00432;&#x00435;&#x00442;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x00441;&#x0043a;&#x0043e;&#x00439; &#x00440;&#x00430;&#x00431;&#x0043e;&#x00442;&#x0044b; &#x00434;&#x0043b;&#x0044f; &#x0043f;&#x00440;&#x00438;&#x00432;&#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00432;&#x0043d;&#x00438;&#x0043c;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x0043c;&#x00435;&#x00441;&#x00442;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x0043d;&#x00430;&#x00441;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043a; &#x0043f;&#x00440;&#x0043e;&#x00431;&#x0043b;&#x00435;&#x0043c;&#x00435; &#x00431;&#x00435;&#x00448;&#x00435;&#x0043d;&#x00441;&#x00442;&#x00432;&#x00430;.</p></sec></trans-abstract></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Rabies is a preventable yet fatal disease that is responsible for approximately 59&#x02009;000 deaths each year.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref> However, widespread underreporting of rabies cases means that the actual number of deaths is likely to be higher. Poor and rural populations are disproportionately affected, with the majority of deaths occurring in children younger than 15&#x000a0;years in Asia and Africa.<xref rid="R2" ref-type="bibr"><sup>2</sup></xref> Ninety-nine per cent of human rabies cases result from dog bites and, once symptoms begin, the disease is almost invariably fatal.<xref rid="R3" ref-type="bibr"><sup>3</sup></xref> Human rabies is preventable through canine vaccination to eliminate rabies at its source or by administering rabies vaccines and immunoglobulin following bites, scratches or saliva exposure from suspected rabid mammals (i.e. postexposure prophylaxis).<xref rid="R4" ref-type="bibr"><sup>4</sup></xref></p><p>Another preventive strategy is pre-exposure prophylaxis, which involves giving a series of intramuscular or intradermal injections of rabies vaccine to prime the immune system. This enables fast recall of memory immune responses once a person is re-exposed to the virus.<xref rid="R4" ref-type="bibr"><sup>4</sup></xref> Moreover, people who have received pre-exposure prophylaxis require fewer doses of postexposure rabies vaccine and can be treated without rabies immunoglobulin, which is costly and difficult to procure.<xref rid="R4" ref-type="bibr"><sup>4</sup></xref> Although preventing rabies in dogs is the most cost-effective way of preventing human rabies deaths, pre-exposure prophylaxis is valuable for people at a high disease risk,<xref rid="R5" ref-type="bibr"><sup>5</sup></xref> particularly in areas where controlling disease in the animal reservoir is difficult or has not been implemented and in areas where access to postexposure prophylaxis and rabies immunoglobulin is unreliable or nonexistent. National pre-exposure prophylaxis programmes for high-risk populations have been implemented in Peru and the Philippines.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="R7" ref-type="bibr"><sup>7</sup></xref></p><p>In 2010, a World Health Organization (WHO) position paper on rabies vaccines called for studies on the feasibility, cost&#x02013;effectiveness and long-term impact of incorporating vaccines derived from cell culture or embryonated eggs into immunization programmes for children where canine rabies is a public health problem.<xref rid="R5" ref-type="bibr"><sup>5</sup></xref> The paper also made recommendations on pre-exposure prophylaxis regimens and on the frequency of booster vaccinations and serological surveillance for at-risk individuals, such as veterinarians. The aim of this study was to review the scientific literature published between 2007 and 2016, as well as field data, to assess the current use and cost&#x02013;effectiveness of pre-exposure rabies prophylaxis (excluding travel vaccines), particularly in children and in high-risk settings, in the context of recommendations made in the 2010 WHO rabies vaccine position paper on pre-exposure prophylaxis and booster vaccine administration.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Literature search</title><p>Our literature review was intended as an update of the review of the evidence on pre-exposure prophylaxis carried out for the 2010 WHO rabies vaccine position paper. Our search was conducted according to preferred reporting items for systematic reviews and meta-analyses guidelines.<xref rid="R8" ref-type="bibr"><sup>8</sup></xref> We searched the PubMed, Centre for Agriculture and Biosciences International, Cochrane Library and Web of Science databases for papers on pre-exposure rabies prophylaxis published between 2007 and 29&#x000a0;January 2016 (<xref ref-type="fig" rid="F1">Fig.&#x000a0;1</xref>) using the search string: &#x0201c;rabies&#x0201d; AND &#x0201c;pre-exposure&#x0201d; AND (&#x0201c;prophylaxis&#x0201d; OR &#x0201c;vaccin*&#x0201d;). We started at 2007 to include studies published after completion of the review for the WHO position paper. Additional references were obtained from citations in relevant publications. We excluded studies that assessed: (i)&#x000a0;postexposure prophylaxis only; or (ii)&#x000a0;pre-exposure prophylaxis either occupationally or in travellers. As we considered the safety and immunogenicity of WHO-recommended vaccination regimens for pre-exposure prophylaxis to be well established, we also excluded papers that confirmed the efficacy of these regimens, unless they specifically assessed the safety and immunogenicity of pre-exposure prophylaxis in children or given in combination with other vaccines. We included any type of study, in any language and from any country that assessed: (i)&#x000a0;pre-exposure prophylaxis in children; (ii)&#x000a0;the cost&#x02013;effectiveness of pre-exposure prophylaxis; (iii)&#x000a0;accelerated or revised pre-exposure prophylaxis regimens; or (iv)&#x000a0;booster vaccination recommendations. Studies that assessed the cost of pre-exposure prophylaxis and its use in children were included regardless of publication date.</p><fig id="F1" fig-type="figure" orientation="portrait" position="float"><label>Fig. 1</label><caption><p><bold>Flowchart showing the selection of publications on pre-exposure rabies prophylaxis, 2007&#x02013;2016</bold></p></caption><p>PREP: pre-exposure prophylaxis; WHO: World Health Organization.</p><graphic xlink:href="BLT.16.173039-F1"/></fig></sec><sec><title>Field data</title><p>We reviewed field data from completed and ongoing pre-exposure prophylaxis campaigns in Peru and the Philippines. In Peru, the campaigns targeted people living in remote areas who were at risk of contracting rabies from vampire bats, whereas in the Philippines they targeted children at risk of dog-transmitted rabies.</p><sec><title>Peru</title><p>In Peru, vampire bats are a common source of rabies: the life-time risk of a bat bite in rural Amazon basin populations is reported to be 41 to 88%.<xref rid="R9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="R10" ref-type="bibr"><sup>10</sup></xref> Outbreak reports and responses are delayed by the remoteness of these populations and controlling rabies in the bat reservoir is challenging.<xref rid="R11" ref-type="bibr"><sup>11</sup></xref> Following a rabies outbreak in 2011, Peru began a mass pre-exposure prophylaxis vaccination campaign that targeted people in Condorcanqui and Bagua Provinces at a high risk of rabies from vampire bats.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref> The risk was regarded as high in these provinces because: (i)&#x000a0;bat bites were common; (ii)&#x000a0;there was evidence of rabies in circulation; (iii)&#x000a0;housing conditions increased vulnerability; (iv)&#x000a0;protective measures among the population were lacking; (v)&#x000a0;tools for vector control were lacking; and (vi)&#x000a0;the remote location of villages delayed health service responses. The campaign involved administering three intramuscular doses of human diploid cell or purified Vero cell vaccine on days&#x000a0;0, 7 and 28. Villages were prioritized to receive the intervention by classifying their epidemiological risk using the following variables: (i)&#x000a0;the endemicity of bat rabies; (ii)&#x000a0;the number of human rabies cases within the previous 6&#x000a0;months; (iii)&#x000a0;the number of livestock rabies cases within the previous 6&#x000a0;months; (iv)&#x000a0;the frequency of vampire bat bites (where there was bite surveillance); (v)&#x000a0;history of postexposure prophylaxis; and (vi)&#x000a0;important, recent ecological changes, such as an increase in the population, a change in the feeding habits of vampire bats, illegal mining or deforestation. Among villages with a history of postexposure prophylaxis interventions, priority was given to those in which the intervention took place more than 1&#x000a0;year previously, those where a low percentage of the population had received postexposure prophylaxis and those close to the site of a recent outbreak or of documented circulation of the rabies virus.</p></sec><sec><title>Philippines</title><p>In the Philippines, pre-exposure rabies prophylaxis is recommended as an additional intervention for high-risk individuals, such as children and people at occupational exposure. In 2007, the Philippine Government implemented a Department of Health recommendation that free routine pre-exposure prophylaxis should be provided for school children aged 5 to 14&#x000a0;years who are living in high-risk areas.<xref rid="R7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="R12" ref-type="bibr"><sup>12</sup></xref> To be included an area had to have: (i)&#x000a0;an incidence of human and canine rabies above the &#x02009;national average; (ii)&#x000a0;an incidence of animal bites above the &#x02009;national average; (iii)&#x000a0;no or low canine vaccination coverage, which was defined as less than &#x02009;30% coverage of the estimated dog population; and (iv)&#x000a0;limited access to postexposure prophylaxis, for example, due to geographical isolation, inadequate treatment facilities or poverty. Schoolchildren were targeted because almost 50% of all rabies exposure in the Philippines occurs in children younger than 15&#x000a0;years. Child deaths due to rabies are associated with poverty and, where postexposure prophylaxis is available, with limited or delayed access to health services. The rationale for pre-exposure prophylaxis was that it: (i)&#x000a0;may protect children who do not receive postexposure prophylaxis, for example, after unremarked exposure (i.e. if their antibody titre at exposure is &#x02265;&#x02009;0.5&#x000a0;IU/mL); (ii)&#x000a0;may protect patients when postexposure prophylaxis is delayed; (iii)&#x000a0;accelerates antibody responses to postexposure prophylaxis; and (iv)&#x000a0;reduces the cost of postexposure prophylaxis by removing the need for rabies immunoglobulin and reducing the number of postexposure prophylaxis doses required from 8 to 2 (<xref ref-type="table" rid="T1">Table&#x000a0;1</xref>). The pre-exposure prophylaxis schedule consisted of administering three intradermal doses of purified Vero cell or chick embryo cell vaccine on days&#x000a0;0, 7 and 28.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Postexposure rabies prophylaxis regimens, by pre-exposure prophylaxis, the Philippines, 2007</title></caption><table frame="hsides" rules="groups"><col width="89" span="1"/><col width="85" span="1"/><col width="106" span="1"/><col width="11" span="1"/><col width="85" span="1"/><col width="109" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Exposure category<sup>a</sup></th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Following pre-exposure rabies prophylaxis<hr/></th><th rowspan="2" valign="top" align="left" scope="col" colspan="1"/><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Without pre-exposure rabies prophylaxis<hr/></th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Rabies vaccine</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Equine rabies immunoglobulin</th><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Rabies vaccine</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Equine rabies immunoglobulin</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Category II</td><td valign="top" align="left" rowspan="1" colspan="1">1 intradermal dose on days 0 and 3 (i.e. 2 doses)</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">2 intradermal doses on days 0, 3, 7 and 28 (i.e. 8 doses)</td><td valign="top" align="left" rowspan="1" colspan="1">No</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Category III</td><td valign="top" align="left" rowspan="1" colspan="1">1 intradermal dose on days 0 and 3 (i.e. 2 doses)</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">2 intradermal doses on days 0, 3, 7 and 28 (i.e. 8 doses)</td><td valign="top" align="left" rowspan="1" colspan="1">Yes, with the volume dependent on body weight</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup> Category-II exposure is defined as nibbling of uncovered skin, minor scratches or abrasions without bleeding and category-III exposure, as single or multiple transdermal bites or scratches, contamination of mucous membranes with saliva from licks, licks on broken skin, exposures to bats.<xref rid="R5" ref-type="bibr"><sup>5</sup></xref></p></table-wrap-foot></table-wrap></sec></sec></sec><sec sec-type="results"><title>Results</title><p>The systematic review of the literature identified 31 publications on pre-exposure rabies prophylaxis that met inclusion criteria (<xref ref-type="table" rid="T2">Table&#x000a0;2</xref>).</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Publications on pre-exposure rabies prophylaxis, systematic review of the literature, 2007&#x02013;2016</title></caption><table frame="hsides" rules="groups"><col width="111" span="1"/><col width="99" span="1"/><col width="77" span="1"/><col width="106" span="1"/><col width="219" span="1"/><col width="133" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Reference</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Publication type</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Publication date</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Study location</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Prophylaxis</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Vaccinees</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Aikimbayev et al.<xref rid="R13" ref-type="bibr"><sup>13</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Meeting report</td><td valign="top" align="left" rowspan="1" colspan="1">2014</td><td valign="top" align="left" rowspan="1" colspan="1">Middle East, Eastern Europe, Central Asia</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">Children and adults</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Banga et al.<xref rid="R14" ref-type="bibr"><sup>14</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2014</td><td valign="top" align="left" rowspan="1" colspan="1">United States</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">Adults</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Brown et al.<xref rid="R15" ref-type="bibr"><sup>15</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2011</td><td valign="top" align="left" rowspan="1" colspan="1">United Kingdom</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">Adults</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Brown et al.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2008</td><td valign="top" align="left" rowspan="1" colspan="1">United Kingdom</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">Adults</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Chulasugandha et al.<xref rid="R17" ref-type="bibr"><sup>17</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2006</td><td valign="top" align="left" rowspan="1" colspan="1">Thailand</td><td valign="top" align="left" rowspan="1" colspan="1">PVRV, PCECV</td><td valign="top" align="left" rowspan="1" colspan="1">Children</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cunha et al.<xref rid="R18" ref-type="bibr"><sup>18</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2010</td><td valign="top" align="left" rowspan="1" colspan="1">Brazil</td><td valign="top" align="left" rowspan="1" colspan="1">PVRV, PCECV</td><td valign="top" align="left" rowspan="1" colspan="1">Adults</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Dodet et al.<xref rid="R19" ref-type="bibr"><sup>19</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Meeting report</td><td valign="top" align="left" rowspan="1" colspan="1">2009</td><td valign="top" align="left" rowspan="1" colspan="1">Viet Nam</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">Children and adults</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Dodet<xref rid="R7" ref-type="bibr"><sup>7</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Meeting report</td><td valign="top" align="left" rowspan="1" colspan="1">2010</td><td valign="top" align="left" rowspan="1" colspan="1">Philippines</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">Children and adults</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hampson et al.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2015</td><td valign="top" align="left" rowspan="1" colspan="1">Worldwide</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">Children and adults</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Jelinek et al.<xref rid="R20" ref-type="bibr"><sup>20</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2015</td><td valign="top" align="left" rowspan="1" colspan="1">Germany</td><td valign="top" align="left" rowspan="1" colspan="1">PCECV, Japanese encephalitis vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Adults</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Kamoltham et al.<xref rid="R21" ref-type="bibr"><sup>21</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2011</td><td valign="top" align="left" rowspan="1" colspan="1">Thailand</td><td valign="top" align="left" rowspan="1" colspan="1">PVRV</td><td valign="top" align="left" rowspan="1" colspan="1">Children </td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Kamoltham et al.<xref rid="R22" ref-type="bibr"><sup>22</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2007</td><td valign="top" align="left" rowspan="1" colspan="1">Thailand</td><td valign="top" align="left" rowspan="1" colspan="1">PCECV</td><td valign="top" align="left" rowspan="1" colspan="1">Children </td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Khawplod et al.<xref rid="R23" ref-type="bibr"><sup>23</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2008</td><td valign="top" align="left" rowspan="1" colspan="1">Thailand</td><td valign="top" align="left" rowspan="1" colspan="1">PCECV, PVRV</td><td valign="top" align="left" rowspan="1" colspan="1">Adults</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Khawplod et al.<xref rid="R24" ref-type="bibr"><sup>24</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2012</td><td valign="top" align="left" rowspan="1" colspan="1">Thailand</td><td valign="top" align="left" rowspan="1" colspan="1">PCECV, PVRV</td><td valign="top" align="left" rowspan="1" colspan="1">Adults</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Khawplod et al.<xref rid="R25" ref-type="bibr"><sup>25</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2007</td><td valign="top" align="left" rowspan="1" colspan="1">Thailand</td><td valign="top" align="left" rowspan="1" colspan="1">PCECV, PVRV</td><td valign="top" align="left" rowspan="1" colspan="1">Adults</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lang et al.<xref rid="R26" ref-type="bibr"><sup>26</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">1997</td><td valign="top" align="left" rowspan="1" colspan="1">Viet Nam</td><td valign="top" align="left" rowspan="1" colspan="1">PVRV</td><td valign="top" align="left" rowspan="1" colspan="1">Children</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lang et al.<xref rid="R27" ref-type="bibr"><sup>27</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2009</td><td valign="top" align="left" rowspan="1" colspan="1">Viet Nam</td><td valign="top" align="left" rowspan="1" colspan="1">PVRV combined with vaccination against diphtheria, tetanus, pertussis (whole-cell vaccine) and poliomyelitis (inactivated vaccine)</td><td valign="top" align="left" rowspan="1" colspan="1">Children</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lau &#x00026; Hohl<xref rid="R28" ref-type="bibr"><sup>28</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2013</td><td valign="top" align="left" rowspan="1" colspan="1">Australia</td><td valign="top" align="left" rowspan="1" colspan="1">PCECV</td><td valign="top" align="left" rowspan="1" colspan="1">Children and adults</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lim &#x00026; Barkham<xref rid="R29" ref-type="bibr"><sup>29</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2010</td><td valign="top" align="left" rowspan="1" colspan="1">Singapore</td><td valign="top" align="left" rowspan="1" colspan="1">PVRV</td><td valign="top" align="left" rowspan="1" colspan="1">Adults</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Liu<xref rid="R30" ref-type="bibr"><sup>30</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2012</td><td valign="top" align="left" rowspan="1" colspan="1">Worldwide</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">Children</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lumbiganon et al.<xref rid="R31" ref-type="bibr"><sup>31</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">1989</td><td valign="top" align="left" rowspan="1" colspan="1">Thailand</td><td valign="top" align="left" rowspan="1" colspan="1">PCECV</td><td valign="top" align="left" rowspan="1" colspan="1">Children</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Malerczyk et al.<xref rid="R32" ref-type="bibr"><sup>32</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2013</td><td valign="top" align="left" rowspan="1" colspan="1">Germany</td><td valign="top" align="left" rowspan="1" colspan="1">PCECV</td><td valign="top" align="left" rowspan="1" colspan="1">Children</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Mills et al.<xref rid="R33" ref-type="bibr"><sup>33</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2011</td><td valign="top" align="left" rowspan="1" colspan="1">Australia</td><td valign="top" align="left" rowspan="1" colspan="1">HDCV</td><td valign="top" align="left" rowspan="1" colspan="1">Children and adults</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Pengsaa et al.<xref rid="R34" ref-type="bibr"><sup>34</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2009</td><td valign="top" align="left" rowspan="1" colspan="1">Thailand</td><td valign="top" align="left" rowspan="1" colspan="1">PCECV combined with Japanese encephalitis vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Children</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ravish et al.<xref rid="R35" ref-type="bibr"><sup>35</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2013</td><td valign="top" align="left" rowspan="1" colspan="1">India</td><td valign="top" align="left" rowspan="1" colspan="1">PCECV</td><td valign="top" align="left" rowspan="1" colspan="1">Children</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Shanbag et al.<xref rid="R36" ref-type="bibr"><sup>36</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2008</td><td valign="top" align="left" rowspan="1" colspan="1">India</td><td valign="top" align="left" rowspan="1" colspan="1">PVRV, PCECV</td><td valign="top" align="left" rowspan="1" colspan="1">Children</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Strady et al.<xref rid="R37" ref-type="bibr"><sup>37</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2009</td><td valign="top" align="left" rowspan="1" colspan="1">France</td><td valign="top" align="left" rowspan="1" colspan="1">HDCV, PVRV</td><td valign="top" align="left" rowspan="1" colspan="1">Children</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sudarshan et al.<xref rid="R38" ref-type="bibr"><sup>38</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2011</td><td valign="top" align="left" rowspan="1" colspan="1">Worldwide</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">Children and adults</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Vashishtha et al.<xref rid="R39" ref-type="bibr"><sup>39</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2014</td><td valign="top" align="left" rowspan="1" colspan="1">India</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">Children</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Vien et al.<xref rid="R40" ref-type="bibr"><sup>40</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2008</td><td valign="top" align="left" rowspan="1" colspan="1">Viet Nam</td><td valign="top" align="left" rowspan="1" colspan="1">PVRV combined with vaccination against diphtheria, tetanus, pertussis (whole-cell vaccine) and poliomyelitis (inactivated vaccine)</td><td valign="top" align="left" rowspan="1" colspan="1">Children</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Wongsaroj et al.<xref rid="R41" ref-type="bibr"><sup>41</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Journal article</td><td valign="top" align="left" rowspan="1" colspan="1">2013</td><td valign="top" align="left" rowspan="1" colspan="1">Thailand</td><td valign="top" align="left" rowspan="1" colspan="1">PVRV</td><td valign="top" align="left" rowspan="1" colspan="1">Adults</td></tr></tbody></table><table-wrap-foot><p>HDCV: human diploid cell vaccine; N/A: not available; PCECV: purified chick embryo cell vaccine; PVRV: purified Vero cell rabies vaccine.</p></table-wrap-foot></table-wrap><sec><title>Safety and immunogenicity in children</title><sec><title>Literature search</title><p>The search identified 11 studies on the safety and immunogenicity of pre-exposure prophylaxis in children aged 2&#x000a0;months to 15&#x000a0;years, including two published before 2007 (<xref ref-type="table" rid="T3">Table&#x000a0;3</xref>). All found it safe and immunogenic in both infants and children. Three found it safe and immunogenic for up to 5&#x000a0;years when given in combination with other childhood vaccines such as those against Japanese encephalitis, diphtheria, tetanus, pertussis and poliomyelitis (both oral and inactivated vaccines).<xref rid="R27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="R34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="R40" ref-type="bibr"><sup>40</sup></xref></p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Pre-exposure rabies prophylaxis in children, systematic review of the literature, 1989&#x02013;2016</title></caption><table frame="hsides" rules="groups"><col width="94" span="1"/><col width="56" span="1"/><col width="56" span="1"/><col width="85" span="1"/><col width="92" span="1"/><col width="85" span="1"/><col width="99" span="1"/><col width="184" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Reference</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Age group (years)</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Vaccine</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Vaccination route</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Regimen</th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Antibody titre (IU/mL)<sup>a</sup><hr/></th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Comments</th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Primary response</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Recall response</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lang et al.,<xref rid="R27" ref-type="bibr"><sup>27</sup></xref> Vien et al.<xref rid="R40" ref-type="bibr"><sup>40</sup></xref> and Lang et al.<xref rid="R26" ref-type="bibr"><sup>26</sup></xref><sup>b</sup></td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;&#x02009;1</td><td valign="top" align="left" rowspan="1" colspan="1">PVRV</td><td valign="top" align="left" rowspan="1" colspan="1">Intramuscular</td><td valign="top" align="left" rowspan="1" colspan="1">2 doses at 2 and 4&#x000a0;months of age</td><td valign="top" align="left" rowspan="1" colspan="1">20.1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;&#x02009;1 (assessed after 5&#x000a0;years)</td><td valign="top" align="left" rowspan="1" colspan="1">Combined with vaccination against diphtheria, tetanus, pertussis and polio (inactivated vaccine)<xref rid="R27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="R40" ref-type="bibr"><sup>40</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Pengsaa et al.<xref rid="R34" ref-type="bibr"><sup>34</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1&#x02013;1.5</td><td valign="top" align="left" rowspan="1" colspan="1">PCECV</td><td valign="top" align="left" rowspan="1" colspan="1">Intramuscular or intradermal</td><td valign="top" align="left" rowspan="1" colspan="1">1 dose on days 0, 7 and 28; or 1 dose on days 0 and 28</td><td valign="top" align="left" rowspan="1" colspan="1">15&#x02013;41 (intramuscular); 4.1&#x02013;8.5 (intradermal)</td><td valign="top" align="left" rowspan="1" colspan="1">103&#x02013;299 (intramuscular); 8.0&#x02013;38 (intradermal) &#x02013; both assessed after 1&#x000a0;year</td><td valign="top" align="left" rowspan="1" colspan="1">Combined with vaccination against Japanese encephalitis: antibody titres were higher following intramuscular than intradermal administration</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lumbiganon et al.<xref rid="R31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><sup>b</sup></td><td valign="top" align="left" rowspan="1" colspan="1">2&#x02013;15</td><td valign="top" align="left" rowspan="1" colspan="1">PCECV</td><td valign="top" align="left" rowspan="1" colspan="1">Intramuscular or intradermal</td><td valign="top" align="left" rowspan="1" colspan="1">1 dose on days 0, 7 and 28</td><td valign="top" align="left" rowspan="1" colspan="1">4.7&#x02013;47</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Antibody titres were higher following intramuscular than intradermal administration</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Kamoltham et al.<xref rid="R21" ref-type="bibr"><sup>21</sup></xref> and Kamoltham et al.<xref rid="R22" ref-type="bibr"><sup>22</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">5&#x02013;8</td><td valign="top" align="left" rowspan="1" colspan="1">PCECV</td><td valign="top" align="left" rowspan="1" colspan="1">Intradermal</td><td valign="top" align="left" rowspan="1" colspan="1">1 dose on days 0, 7 and 28; or 1 dose on days 0 and 28</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;&#x02009;2</td><td valign="top" align="left" rowspan="1" colspan="1">8.9&#x02013;27.3 (assessed after &#x02265;&#x02009;1&#x000a0;year)</td><td valign="top" align="left" rowspan="1" colspan="1">All children had an antibody titre &#x0003e;&#x02009;0.5&#x000a0;IU/mL within 14&#x000a0;days of the booster dose, regardless of the time interval and the number of doses initially received</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ravish et al.<xref rid="R35" ref-type="bibr"><sup>35</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">5&#x02013;10</td><td valign="top" align="left" rowspan="1" colspan="1">PCECV</td><td valign="top" align="left" rowspan="1" colspan="1">Intradermal</td><td valign="top" align="left" rowspan="1" colspan="1">1 dose on days 0, 7 and 21</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">80.4% of children completed treatment; there were no serious adverse reactions</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Shanbag et al.<xref rid="R36" ref-type="bibr"><sup>36</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">6&#x02013;13</td><td valign="top" align="left" rowspan="1" colspan="1">PVRV or PCECV</td><td valign="top" align="left" rowspan="1" colspan="1">Intramuscular</td><td valign="top" align="left" rowspan="1" colspan="1">1 dose on days 0, 7 and 28</td><td valign="top" align="left" rowspan="1" colspan="1">12.2&#x02013;14.5</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">None</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Strady et al.<xref rid="R37" ref-type="bibr"><sup>37</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">12&#x02013;79</td><td valign="top" align="left" rowspan="1" colspan="1">HDCV or PVRV</td><td valign="top" align="left" rowspan="1" colspan="1">Intramuscular</td><td valign="top" align="left" rowspan="1" colspan="1">1 dose on days 0, 7 and 28; or 1 dose on days 0 and 28</td><td valign="top" align="left" rowspan="1" colspan="1">0.1&#x02013;48 (assessed after 1&#x000a0;year)</td><td valign="top" align="left" rowspan="1" colspan="1">51 (3 doses); 13 (2 doses) &#x02013; both assessed after 1&#x000a0;year</td><td valign="top" align="left" rowspan="1" colspan="1">None</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Malerczyk et al.<xref rid="R32" ref-type="bibr"><sup>32</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c; 15</td><td valign="top" align="left" rowspan="1" colspan="1">PCECV</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">This review of &#x0003e;&#x02009;1200 children treated over &#x0003e;&#x02009;25&#x000a0;years concluded that the vaccine was safe and immunogenic, whether given intramuscularly or intradermally</td></tr></tbody></table><table-wrap-foot><p>HDCV: human diploid cell vaccine; N/A: not applicable; ND: not determined; PCECV: purified chick embryo cell vaccine; PVRV: purified Vero cell rabies vaccine.</p><p><sup>a</sup> The values are either geometric means or ranges, as appropriate.</p><p><sup>b</sup> Although this study was published before 2007, it has been included because the results are still relevant.</p></table-wrap-foot></table-wrap></sec></sec><sec><title>High-risk settings</title><sec><title>Literature search</title><p>Pre-exposure prophylaxis programmes for high-risk populations, and especially children, were strongly recommended in reports of expert meetings on rabies and child health in Asia and the Middle East.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="R13" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="R19" ref-type="bibr"><sup>19</sup></xref> In India, the Academy of Pediatrics called for its inclusion in the immunization schedule for high-risk children younger than 18&#x000a0;years.<xref rid="R39" ref-type="bibr"><sup>39</sup></xref></p></sec><sec><title>Peru</title><p>In 2011, pre-exposure prophylaxis was administered in 286 localities in the Amazonas Region: 86% were in Condorcanqui Province and 14% were in Bagua Province. In total, 13&#x02009;986 people were immunized. In these areas, the number of rabies deaths dropped from 13 in 2010 and 20 in 2011 to zero child deaths and only two adult deaths (both had refused vaccination) in 2012.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref>
<xref ref-type="fig" rid="F2">Fig.&#x000a0;2</xref> shows the number of human rabies deaths in Bagua and Condorcanqui Provinces between 1975 and 2015. The number of reported bat bites, which is used as a surrogate for rabies exposure, decreased between 2010 and 2013 (<xref ref-type="table" rid="T4">Table&#x000a0;4</xref>) but there was no change in the risk factors for bites, such as the number of houses bats could enter. In areas adjacent to the Amazonas Region, in which pre-exposure prophylaxis was not implemented, there were outbreaks of human rabies in 2011, 2013 and 2015 (unpublished data, 2015). The programme was extended until 2015 to cover an additional 423 communities in Bagua and Condorcanqui Provinces at a high risk of rabies. By 2015, 71&#x02009;400 people in the Amazonas Region (i.e. 86% of the population) had received pre-exposure prophylaxis and, by the end of 2014, 121&#x02009;285 people (i.e. 76% of the target population) in Cusco, Jun&#x000ed;n and Loreto Regions had also received it. No serious adverse events were reported.</p><fig id="F2" fig-type="figure" orientation="portrait" position="float"><label>Fig. 2</label><caption><p><bold>Human rabies deaths, Amazonas Region, Peru, 1975&#x02013;2015</bold></p></caption><p>Notes: The Amazonas Region is the political division of Peru that includes Condorcanqui and Bagua Provinces, not the Amazon ecological region. All human rabies deaths reported in the figure occurred in Bagua and Condorcanqui Provinces.</p><graphic xlink:href="BLT.16.173039-F2"/></fig><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><title>Bat bites by region, Peru, 2009&#x02013;2013<xref rid="R6" ref-type="bibr"><bold><sup>6</sup></bold></xref></title></caption><table frame="hsides" rules="groups"><col width="70" span="1"/><col width="55" span="1"/><col width="55" span="1"/><col width="55" span="1"/><col width="55" span="1"/><col width="55" span="1"/><col width="56" span="1"/><col width="66" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Region</th><th colspan="6" valign="top" align="center" scope="colgroup" rowspan="1">No. of bat bites reported<hr/></th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">% of all reported bat bites</th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">2009</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">2010</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">2011</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">2012</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">2013</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Amazonas</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;576</td><td valign="top" align="center" rowspan="1" colspan="1">5&#x000a0;714</td><td valign="top" align="center" rowspan="1" colspan="1">2&#x000a0;145</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;733</td><td valign="top" align="center" rowspan="1" colspan="1">833</td><td valign="top" align="center" rowspan="1" colspan="1">12&#x02009;001</td><td valign="top" align="center" rowspan="1" colspan="1">59.2</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cusco</td><td valign="top" align="center" rowspan="1" colspan="1">50</td><td valign="top" align="center" rowspan="1" colspan="1">169</td><td valign="top" align="center" rowspan="1" colspan="1">36</td><td valign="top" align="center" rowspan="1" colspan="1">441</td><td valign="top" align="center" rowspan="1" colspan="1">20</td><td valign="top" align="center" rowspan="1" colspan="1">716</td><td valign="top" align="center" rowspan="1" colspan="1">3.5</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Loreto</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;122</td><td valign="top" align="center" rowspan="1" colspan="1">856</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;458</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;380</td><td valign="top" align="center" rowspan="1" colspan="1">590</td><td valign="top" align="center" rowspan="1" colspan="1">5&#x000a0;406</td><td valign="top" align="center" rowspan="1" colspan="1">26.7</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Junin</td><td valign="top" align="center" rowspan="1" colspan="1">119</td><td valign="top" align="center" rowspan="1" colspan="1">415</td><td valign="top" align="center" rowspan="1" colspan="1">179</td><td valign="top" align="center" rowspan="1" colspan="1">142</td><td valign="top" align="center" rowspan="1" colspan="1">29</td><td valign="top" align="center" rowspan="1" colspan="1">884</td><td valign="top" align="center" rowspan="1" colspan="1">4.4</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Others</td><td valign="top" align="center" rowspan="1" colspan="1">465</td><td valign="top" align="center" rowspan="1" colspan="1">224</td><td valign="top" align="center" rowspan="1" colspan="1">295</td><td valign="top" align="center" rowspan="1" colspan="1">229</td><td valign="top" align="center" rowspan="1" colspan="1">41</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;254</td><td valign="top" align="center" rowspan="1" colspan="1">6.2</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">All</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x000a0;332</td><td valign="top" align="center" rowspan="1" colspan="1">7&#x000a0;378</td><td valign="top" align="center" rowspan="1" colspan="1">4&#x000a0;113</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x000a0;925</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;513</td><td valign="top" align="center" rowspan="1" colspan="1">20&#x02009;261</td><td valign="top" align="center" rowspan="1" colspan="1">100.0</td></tr></tbody></table></table-wrap></sec><sec><title>Philippines</title><p>By April 2010, the routine pre-exposure prophylaxis immunization programme had achieved an average coverage of 47.25% in the target population: 21&#x02009;637 high-risk children in 31 schools in seven regions were immunized (unpublished data, 2010). In the town of Cabusao, 188 schoolchildren received at least one vaccine dose (i.e. 86% of those eligible) and 90% of the 188 completed the pre-exposure prophylaxis regimen. Subsequently, 3.5% received postexposure prophylaxis within 3&#x000a0;years following suspected exposure. The programme was stopped in 2011 because a large increase in rabies exposure led to a vaccine shortage and priority was given to the immunization of people involved in canine vaccination campaigns. Pre-exposure prophylaxis of schoolchildren was planned to restart in 2016.</p></sec></sec><sec><title>Cost&#x02013;effectiveness</title><sec><title>Literature search</title><p>Few recent studies have assessed the cost&#x02013;effectiveness of pre-exposure rabies prophylaxis. One study estimated the annual global direct cost of administering postexposure rabies prophylaxis at 1.7&#x000a0;billion United States dollars (US$), plus an additional US$&#x000a0;1.3 billion in lost income.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref> In a cost assessment of pre-exposure prophylaxis, researchers showed that it would be cost-neutral if 1% of children were exposed to rabies each year and if the price of the vaccine did not exceed US$&#x000a0;1.32 per dose, once the cost of postexposure prophylaxis boosters required after exposure was taken into account.<xref rid="R30" ref-type="bibr"><sup>30</sup></xref> The acceptable vaccine cost increased in proportion to the incidence of rabies. In a Thai study, the estimated cost of pre-exposure prophylaxis for children ranged from US$&#x000a0;2.00 to 7.25 per child depending on the schedule and vaccine used: there was an additional cost of US$&#x000a0;18.00 to 23.50 per child if postexposure prophylaxis was required later.<xref rid="R17" ref-type="bibr"><sup>17</sup></xref> Pre-exposure prophylaxis became cost-comparable to the least expensive postexposure schedule (i.e. intradermal immunization without rabies immunoglobulin) when the annual risk of a dog bite was approximately 23%. If equine or human rabies immunoglobulin was used with postexposure vaccines, pre-exposure prophylaxis was cost-comparable when the annual risk of a dog bite was 7% or 3%, respectively. As over 30% of Thai children had been bitten by a dog by the age of 15&#x000a0;years, it was estimated that the actual incidence of dog bites in the population of central Thailand was only 2.3% per year. Consequently, pre-exposure prophylaxis with currently licensed vaccines would not be cost-effective in this setting.</p></sec><sec><title>Peru</title><p>The cost of the mass pre-exposure prophylaxis campaign was estimated to be US$&#x000a0;4&#x02009;111&#x02009;000, of which US$&#x000a0;3&#x02009;560&#x02009;000 was the cost of the vaccine. The average cost per immunized person was US$&#x000a0;69. By assuming that the risk of rabies was constant (i.e. the rabies virus remained in circulation and the risk of a bat bite was unchanged) and that, each year, rabies caused 20 deaths per 50&#x02009;000 people in Condorcanqui Province without pre-exposure prophylaxis, we estimated the cost of pre-exposure prophylaxis to be US$&#x000a0;205&#x02009;000 per life saved after the first year.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref> After 5&#x000a0;years, the cost decreased to US$&#x000a0;41&#x02009;000 per life saved. This amount is comparable to the cost of treating one rabies-infected individual, including the cost of transport, laboratory diagnosis and hospitalization. The use of intradermal vaccinations would reduce the vaccination cost by 80%. However, intramuscular vaccination continues to be used in Peru because: (i)&#x000a0;there is no shortage of rabies vaccine in the country; (ii)&#x000a0;staff have not been trained in the multiple uses of rabies vaccine vials for intradermal administration; and (iii)&#x000a0;the national authorities elected to use the intramuscular route to minimize the risk of errors in vaccine administration.</p></sec><sec><title>Philippines</title><p>Pre-exposure prophylaxis with three doses of purified Vero cell or chick embryo cell vaccine was estimated to cost US$&#x000a0;4.77 per patient (unpublished data, 2015; (<xref ref-type="table" rid="T5">Table&#x000a0;5</xref>). For a patient weighing between 26 and 50&#x000a0;kg, pre-exposure prophylaxis reduced the cost of postexposure prophylaxis by up to 38% following category-II exposure (i.e. &#x0201c;nibbling of uncovered skin, minor scratches or abrasions without bleeding&#x0201d;)<xref rid="R5" ref-type="bibr"><sup>5</sup></xref> and by up to 85% following category-III exposure (i.e. &#x0201c;single or multiple transdermal bites or scratches, contamination of mucous membranes with saliva from licks, licks on broken skin, exposures to bats&#x0201d;),<xref rid="R5" ref-type="bibr"><sup>5</sup></xref> after the cost of pre-exposure prophylaxis was taken into account.</p><table-wrap id="T5" orientation="portrait" position="float"><label>Table 5</label><caption><title>Cost of postexposure rabies prophylaxis, the Philippines, 2007</title></caption><table frame="hsides" rules="groups"><col width="90" span="1"/><col width="141" span="1"/><col width="155" span="1"/><col width="11" span="1"/><col width="115" span="1"/><col width="92" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Exposure category<sup>a</sup></th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Cost in US$ per patient (treatment specifics)<hr/></th><th rowspan="2" valign="top" align="left" scope="col" colspan="1"/><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Savings per patient (weight range: 26&#x02013;50&#x000a0;kg) who had pre-exposure prophylaxis<hr/></th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Patients who had pre-exposure prophylaxis</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Patients (weight range: 26&#x02013;50&#x000a0;kg) who did not have pre-exposure prophylaxis</th><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">US$</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">(%)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Category II</td><td valign="top" align="center" rowspan="1" colspan="1">3.19 (2 intradermal doses of PCECV or PVRV at US$&#x000a0;1.59 per dose; no RIG)</td><td valign="top" align="center" rowspan="1" colspan="1">12.76 (8 intradermal doses of PCECV or PVRV at US$&#x000a0;1.59 per dose; no RIG)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">4.80</td><td valign="top" align="center" rowspan="1" colspan="1">38</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Category III</td><td valign="top" align="center" rowspan="1" colspan="1">3.19 (2 intradermal doses of PCECV or PVRV at US$&#x000a0;1.59 per dose; no RIG)</td><td valign="top" align="center" rowspan="1" colspan="1">51.76 (8 intradermal doses PCECV or PVRV at US$&#x000a0;1.59 per dose; 2 vials of ERIG at US$&#x000a0;19.52 per vial)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">43.80</td><td valign="top" align="center" rowspan="1" colspan="1">85</td></tr></tbody></table><table-wrap-foot><p>ERIG: equine rabies immunoglobulin; PCECV: purified chick embryo cell vaccine; PVRV: purified Vero cell rabies vaccine; RIG: rabies immunoglobulin; US$: United States dollar.</p><p><sup>a</sup> Category-II exposure is defined as nibbling of uncovered skin, minor scratches or abrasions without bleeding and category-III exposure, as single or multiple transdermal bites or scratches, contamination of mucous membranes with saliva from licks, licks on broken skin, exposures to bats.<xref rid="R5" ref-type="bibr"><sup>5</sup></xref></p><p>Notes: The percentage saving is the cost saving divided by the cost of postexposure prophylaxis in a patient who did not have pre-exposure prophylaxis&#x02009;&#x000d7;&#x02009;100. Prices were converted at a rate of US$&#x000a0;1 per 47.65 Philippine pesos. The cost of postexposure rabies prophylaxis was the cost at bite centres taking part in a national pre-exposure rabies prophylaxis programme for high-risk populations, which was lower than in hospitals and private bite centres. The cost of pre-exposure rabies prophylaxis was US$&#x000a0;4.77 per patient (US$&#x000a0;1.59 per intradermal dose&#x02009;&#x000d7;&#x02009;3). In calculating savings, the cost of pre-exposure prophylaxis was taken into account.</p></table-wrap-foot></table-wrap></sec></sec><sec><title>Accelerated or revised regimens</title><p>Nine studies investigated the safety and immunogenicity of an accelerated or revised pre-exposure prophylaxis regimen (<xref ref-type="table" rid="T6">Table&#x000a0;6</xref>; available at <ext-link ext-link-type="uri" xlink:href="http://www.who.int/bulletin/volume/95/03/16-173039">http://www.who.int/bulletin/volume/95/03/16-173039</ext-link>). Administering all vaccine doses within 1&#x000a0;week<xref rid="R22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="R23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="R28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="R33" ref-type="bibr"><sup>33</sup></xref> or in one<xref rid="R23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="R24" ref-type="bibr"><sup>24</sup></xref> or two visits<xref rid="R41" ref-type="bibr"><sup>41</sup></xref> elicited an adequate antibody titre of 0.5&#x000a0;IU/mL or higher for up to 1&#x000a0;year,<xref rid="R23" ref-type="bibr"><sup>23</sup></xref><sup>&#x02013;</sup><xref rid="R25" ref-type="bibr"><sup>25</sup></xref><sup>,</sup><xref rid="R28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="R33" ref-type="bibr"><sup>33</sup></xref> even when given in combination with Japanese encephalitis vaccine.<xref rid="R20" ref-type="bibr"><sup>20</sup></xref> Adequate titres were observed in people who received a total dose of at least 2&#x000a0;IU of intradermal pre-exposure prophylaxis.<xref rid="R15" ref-type="bibr"><sup>15</sup></xref> Factors associated with an inadequate antibody titre included: (i)&#x000a0;a period of more than 21&#x000a0;days between the first and third doses; (ii)&#x000a0;male sex; (iii)&#x000a0;vaccine type or manufacturer; and (iv)&#x000a0;a body mass index of 25&#x000a0;kg/m<sup>2</sup> or higher.<xref rid="R14" ref-type="bibr"><sup>14</sup></xref></p><table-wrap id="T6" specific-use="online" orientation="portrait" position="float"><label>Table 6</label><caption><title>Accelerated or revised pre-exposure rabies prophylaxis, systematic review of the literature, 2007&#x02013;2016</title></caption><table frame="hsides" rules="groups"><col width="87" span="1"/><col width="85" span="1"/><col width="85" span="1"/><col width="63" span="1"/><col width="85" span="1"/><col width="184" span="1"/><col width="106" span="1"/><col width="116" span="1"/><col width="103" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Reference</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Study type</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">No. of study participants</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Vaccine</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Vaccination route</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Regimen</th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Antibody titre (IU/mL)<hr/></th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Comments</th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Primary response</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">After booster vaccination</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Kamoltham et al.<xref rid="R22" ref-type="bibr"><sup>22</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Randomized, open-label phase-II clinical trial</td><td valign="top" align="left" rowspan="1" colspan="1">703</td><td valign="top" align="left" rowspan="1" colspan="1">PCECV</td><td valign="top" align="left" rowspan="1" colspan="1">Intradermal</td><td valign="top" align="left" rowspan="1" colspan="1">(i)&#x000a0;0.1&#x000a0;mL on days 0 and 28; and (ii)&#x000a0;0.1&#x000a0;mL on days 0, 7 and 28 </td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">(i) 10.76 (GMT; range: 1.87&#x02013;37); and (ii) 22.12 (GMT; range: 2.13&#x02013;199) &#x02013; both measured 14 days after receiving 0.1&#x000a0;mL PCECV booster vaccination on days 365 and 368</td><td valign="top" align="left" rowspan="1" colspan="1">Seroconversion<sup>a</sup> occurred within 14 days of booster vaccination in all vaccinees who received two or three doses of pre-exposure prophylaxis</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Khawplod et al.<xref rid="R25" ref-type="bibr"><sup>25</sup></xref> and Khawplod et al.<xref rid="R23" ref-type="bibr"><sup>23</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Randomized, prospective</td><td valign="top" align="left" rowspan="1" colspan="1">96 and 52</td><td valign="top" align="left" rowspan="1" colspan="1">PVRV and PCECV</td><td valign="top" align="left" rowspan="1" colspan="1">Intradermal and intramuscular</td><td valign="top" align="left" rowspan="1" colspan="1">(i)&#x000a0;0.1&#x000a0;mL PVRV intradermally at two sites on days 0, 7 and 28; (ii)&#x000a0;0.1&#x000a0;mL PVRV intradermally at two sites on days 0, 3 and 7; (iii)&#x000a0;1.0&#x000a0;mL PVRV intramuscularly at one site on days 0, 3 and 7; (iv)&#x000a0;0.1&#x000a0;mL PVRV intradermally at two sites on day 0; (v)&#x000a0;0.1&#x000a0;mL PVRV intradermally at two sites on days 0, 3 and 7 and at one site on days 28 and 90; and (vi)&#x000a0;0.1&#x000a0;mL PCECV intradermally at two sites on days 0, 3 and 7 and at one site on days 28 and 90</td><td valign="top" align="left" rowspan="1" colspan="1">(i)&#x000a0;0.96 (GMT) on day 360; (ii)&#x000a0;1.12 (GMT) on day 360; (iii)&#x000a0;0.97 (GMT) on day 360; (iv)&#x000a0;0.41 (GMT) on day 360; (v)&#x000a0;5.84 (GMT) on day 28; and (vi)&#x000a0;5.96 (GMT) on day 28</td><td valign="top" align="left" rowspan="1" colspan="1">(i)&#x000a0;49.39 (GMT) on day 374; (ii)&#x000a0;105.08 (GMT) on day 374; (iii)&#x000a0;125.00 (GMT) on day 374; (iv)&#x000a0;51.96 (GMT) on day 374; (v)&#x000a0;ND; and (vi)&#x000a0;ND &#x02013; all measured after booster vaccination with 0.1&#x000a0;mL PVRV intradermally at two sites on days 360 and 363</td><td valign="top" align="left" rowspan="1" colspan="1">Seroconversion<sup>a</sup> occurred after booster vaccination with all regimens; the two studies used the same regimens and reported the same data</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Mills et al.<xref rid="R33" ref-type="bibr"><sup>33</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Case series</td><td valign="top" align="left" rowspan="1" colspan="1">420</td><td valign="top" align="left" rowspan="1" colspan="1">HDCV</td><td valign="top" align="left" rowspan="1" colspan="1">Intradermal</td><td valign="top" align="left" rowspan="1" colspan="1">0.1&#x000a0;mL at two sites on days 0 and 7</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;&#x02009;0.5 in 94.5% of vaccinees on day 28</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Seroconversion<sup>a</sup> occurred in 94.5% of vaccinees by day&#x000a0;28 following a two-visit pre-exposure prophylaxis regimen</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Khawplod et al.<xref rid="R24" ref-type="bibr"><sup>24</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Abbreviated, prospective</td><td valign="top" align="left" rowspan="1" colspan="1">109</td><td valign="top" align="left" rowspan="1" colspan="1">PCECV</td><td valign="top" align="left" rowspan="1" colspan="1">Intradermal and intramuscular</td><td valign="top" align="left" rowspan="1" colspan="1">(i)&#x000a0;0.1&#x000a0;mL intradermally on days 0, 7 and 21, followed by a 1.0-mL intramuscular booster on days 360 and 363; (ii)&#x000a0;0.1&#x000a0;mL intradermally on days 0, 7 and 21, followed by a 0.1-mL intradermal booster at four sites on day 360; (iii)&#x000a0;0.1&#x000a0;mL intradermally at two sites on day 0, followed by a 1.0-mL intramuscular booster on days 360 and 363; (iv)&#x000a0;0.1&#x000a0;mL intradermally at two sites on day 0, followed by a 0.1-mL intradermal booster at four sites on day 360; (v)&#x000a0;1.0&#x000a0;mL intramuscularly on day 0, followed by a 1.0-mL intramuscular booster on days 360 and 363; and (vi)&#x000a0;1.0&#x000a0;mL intramuscularly on day 0, followed by a 0.1-mL intradermal booster at four sites on day 360</td><td valign="top" align="left" rowspan="1" colspan="1">(i)&#x000a0;0.49 (NAb); (ii)&#x000a0;0.30 (NAb); (iii)&#x000a0;0.15 (NAb); (iv)&#x000a0;0.10 (NAb); (v)&#x000a0;0.08 (NAb); and &#x02009;(vi)&#x000a0;0.11 (NAb) &#x02013; all measured before booster vaccination on day 360</td><td valign="top" align="left" rowspan="1" colspan="1">(i)&#x000a0;11.27 (NAb); (ii)&#x000a0;42.49 (NAb); (iii)&#x000a0;9.71 (NAb); (iv)&#x000a0;11.96 (NAb); (vi)&#x000a0;10.13 (NAb); and &#x02009;(vi)&#x000a0;13.33 (NAb) &#x02013; all measured 7&#x000a0;days after booster vaccination</td><td valign="top" align="left" rowspan="1" colspan="1">Seroconversion<sup>a</sup> occurred within 7&#x000a0;days of booster vaccination for all regimens assessed</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lau &#x00026; Hohl<xref rid="R28" ref-type="bibr"><sup>28</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Case series</td><td valign="top" align="left" rowspan="1" colspan="1">54</td><td valign="top" align="left" rowspan="1" colspan="1">PCECV</td><td valign="top" align="left" rowspan="1" colspan="1">Intradermal</td><td valign="top" align="left" rowspan="1" colspan="1">0.1&#x000a0;mL at two sites on days 0 and 7</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;&#x02009;0.5 in 94.4% of vaccinees on day 28</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Seroconversion<sup>a</sup> occurred in 94.4% of vaccinees by day 28</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Wongsaroj et al.<xref rid="R41" ref-type="bibr"><sup>41</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Randomized, prospective</td><td valign="top" align="left" rowspan="1" colspan="1">55</td><td valign="top" align="left" rowspan="1" colspan="1">PVRV</td><td valign="top" align="left" rowspan="1" colspan="1">Intradermal and intramuscular</td><td valign="top" align="left" rowspan="1" colspan="1">(i)&#x000a0;0.1&#x000a0;mL intradermally at two sites on days 0 and 21; and (ii)&#x000a0;0.5&#x000a0;mL intramuscularly on days 0, 7 and 21</td><td valign="top" align="left" rowspan="1" colspan="1">(i)&#x000a0;4.51 (NAb); and (ii)&#x000a0;6.74 (NAb) &#x02013; both measured on day 35</td><td valign="top" align="left" rowspan="1" colspan="1">(i)&#x000a0;14.38 (GMT); and (ii)&#x000a0;14.06 (GMT) &#x02013; both measured 14 days after booster vaccination with 0.1&#x000a0;mL PVRV intradermally on days 360 and 363</td><td valign="top" align="left" rowspan="1" colspan="1">Seroconversion<sup>a</sup> occurred within 14 days of booster vaccination with both regimens</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Jelinek<xref rid="R20" ref-type="bibr"><sup>20</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Randomized, observer-blinded, multicentre</td><td valign="top" align="left" rowspan="1" colspan="1">661</td><td valign="top" align="left" rowspan="1" colspan="1">PCECV</td><td valign="top" align="left" rowspan="1" colspan="1">Intramuscular</td><td valign="top" align="left" rowspan="1" colspan="1">(i)&#x000a0;1.0&#x000a0;mL on days 0, 7 and 28, with standard Japanese encephalitis vaccine regimen; (ii)&#x000a0;1.0&#x000a0;mL on days 0, 3 and 7, with accelerated Japanese encephalitis vaccine regimen; and (iii)&#x000a0;1.0&#x000a0;mL PCECV alone on days 0, 7 and 28</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;&#x02009;0.5 in 97&#x02013;100% of vaccinees on day 57</td><td valign="top" align="left" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1">Seroconversion<sup>a</sup> occurred in 97&#x02013;100% of vaccinees by day 57</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Brown et al.<xref rid="R15" ref-type="bibr"><sup>15</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Cohort study</td><td valign="top" align="left" rowspan="1" colspan="1">12</td><td valign="top" align="left" rowspan="1" colspan="1">PVRV (booster dose)</td><td valign="top" align="left" rowspan="1" colspan="1">Intradermal</td><td valign="top" align="left" rowspan="1" colspan="1">People with an antibody titre &#x0003c; 0.5&#x000a0;IU/mL following initial pre-exposure prophylaxis received one booster dose after 2&#x000a0;years to give a total vaccine dose &#x02265;&#x02009;2&#x000a0;IU</td><td valign="top" align="left" rowspan="1" colspan="1">0.18 (mean) before booster</td><td valign="top" align="left" rowspan="1" colspan="1">17.33 (mean) after booster</td><td valign="top" align="left" rowspan="1" colspan="1">Seroconversion<sup>a</sup> occurred in all vaccinees who received &#x02265;&#x02009;2&#x000a0;IU of vaccine</td></tr></tbody></table><table-wrap-foot><p>HDCV: human diploid cell vaccine; GMT: geometric mean titre; NAb: neutralizing antibody; ND: not determined; PCECV: purified chick embryo cell vaccine; PVRV: purified Vero cell rabies vaccine.</p><p><sup>a</sup> Seroconversion was defined as an antibody titre &#x0003e;&#x02009;0.5&#x000a0;IU/mL.</p></table-wrap-foot></table-wrap></sec><sec><title>Booster vaccinations</title><p>Four studies investigated recommendations on booster vaccines (<xref ref-type="table" rid="T7">Table&#x000a0;7</xref>; available at <ext-link ext-link-type="uri" xlink:href="http://www.who.int/bulletin/volume/95/03/16-173039">http://www.who.int/bulletin/volume/95/03/16-173039</ext-link>). They concluded that: (i)&#x000a0;the interval between booster vaccinations could be extended by up to 10&#x000a0;years;<xref rid="R16" ref-type="bibr"><sup>16</sup></xref> (ii)&#x000a0;serological surveillance or booster vaccination after 1&#x000a0;year is advisable for people in high-risk occupations;<xref rid="R29" ref-type="bibr"><sup>29</sup></xref> (iii)&#x000a0;serological testing after the third intramuscular or intradermal pre-exposure prophylaxis dose is unnecessary;<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> and (iv)&#x000a0;healthy subjects may not require postexposure prophylaxis boosters on re-exposure to rabies for up to 3&#x000a0;months after pre-exposure or previous postexposure prophylaxis.<xref rid="R38" ref-type="bibr"><sup>38</sup></xref></p><table-wrap id="T7" specific-use="online" orientation="portrait" position="float"><label>Table 7</label><caption><title>Booster rabies vaccination recommendations, systematic review of the literature, 2007&#x02013;2016</title></caption><table frame="hsides" rules="groups"><col width="97" span="1"/><col width="85" span="1"/><col width="79" span="1"/><col width="140" span="1"/><col width="148" span="1"/><col width="177" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Reference</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Study type</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">No. of participants</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Vaccination regimen</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Antibody titre (IU/mL)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Conclusion</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Brown et al.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Retrospective cohort study</td><td valign="top" align="left" rowspan="1" colspan="1">89</td><td valign="top" align="left" rowspan="1" colspan="1">Intradermal pre-exposure prophylaxis</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02265;&#x02009;0.5 after a mean of 5&#x000a0;years (range: 1&#x02013;12) in 100% of vaccinees who received &#x02265;&#x02009;0.6&#x000a0;mL of vaccine over two or three visits</td><td valign="top" align="left" rowspan="1" colspan="1">Intradermal pre-exposure prophylaxis with 0.6&#x000a0;mL of vaccine over three visits could extend the interval before booster vaccination to 10&#x000a0;years</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lim &#x00026; Barkham,<xref rid="R29" ref-type="bibr"><sup>29</sup></xref> Cohort 1</td><td valign="top" align="left" rowspan="1" colspan="1">Retrospective cohort study</td><td valign="top" align="left" rowspan="1" colspan="1">66</td><td valign="top" align="left" rowspan="1" colspan="1">Three doses of PVRV pre-exposure prophylaxis</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;&#x02009;0.5 in 60.6% of vaccinees after 1&#x000a0;year</td><td valign="top" align="left" rowspan="1" colspan="1">Serological surveillance or a booster vaccination 1&#x000a0;year after primary pre-exposure prophylaxis is advised for people in high-risk occupations </td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lim &#x00026; Barkham,<xref rid="R29" ref-type="bibr"><sup>29</sup></xref> Cohort 2</td><td valign="top" align="left" rowspan="1" colspan="1">Retrospective cohort study</td><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1">Four doses: three of pre-exposure prophylaxis and one booster dose given after a median of 10&#x000a0;years (range: 3&#x02013;18)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;&#x02009;0.5 in 100% of vaccinees after a median of 10&#x000a0;years (range: 3&#x02013;18)</td><td valign="top" align="left" rowspan="1" colspan="1">Serological surveillance or a booster vaccination 1&#x000a0;year after primary pre-exposure prophylaxis is advised for people in high-risk occupations</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cunha et al.,<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> Group 1</td><td valign="top" align="left" rowspan="1" colspan="1">Randomized controlled study</td><td valign="top" align="left" rowspan="1" colspan="1">65</td><td valign="top" align="left" rowspan="1" colspan="1">Intradermal pre-exposure prophylaxis</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;&#x02009;0.5 in 97% of vaccinees after a mean of 10&#x000a0;days and &#x0003e;&#x02009;0.5 in 20&#x02013;25% after a mean of 180&#x000a0;days</td><td valign="top" align="left" rowspan="1" colspan="1">Serological testing after the third dose of pre-exposure prophylaxis is unnecessary<sup>a</sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cunha et al.,<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> Group 2</td><td valign="top" align="left" rowspan="1" colspan="1">Randomized controlled study</td><td valign="top" align="left" rowspan="1" colspan="1">62</td><td valign="top" align="left" rowspan="1" colspan="1">Intramuscular pre-exposure prophylaxis</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;&#x02009;0.5 in 100% of vaccinees after a mean of 10&#x000a0;days and &#x0003e;&#x02009;0.5 in 63&#x02013;65% after a mean of 180&#x000a0;days</td><td valign="top" align="left" rowspan="1" colspan="1">Serological testing after the third dose of pre-exposure prophylaxis is unnecessary<sup>a</sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sudarshan et al.,<xref rid="R38" ref-type="bibr"><sup>38</sup></xref> Group 1</td><td valign="top" align="left" rowspan="1" colspan="1">Literature review</td><td valign="top" align="left" rowspan="1" colspan="1">577</td><td valign="top" align="left" rowspan="1" colspan="1">Pre-exposure prophylaxis</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;&#x02009;0.5 in 100% after a mean of 3&#x000a0;months</td><td valign="top" align="left" rowspan="1" colspan="1">It may be safe not to administer postexposure prophylaxis in healthy individuals re-exposed to rabies within 3&#x000a0;months of pre-exposure or previous postexposure prophylaxis</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sudarshan et al.,<xref rid="R38" ref-type="bibr"><sup>38</sup></xref> Group 2</td><td valign="top" align="left" rowspan="1" colspan="1">Literature review</td><td valign="top" align="left" rowspan="1" colspan="1">2795</td><td valign="top" align="left" rowspan="1" colspan="1">Postexposure prophylaxis</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e; 0.5 in 99.9% after a mean of 3&#x000a0;months</td><td valign="top" align="left" rowspan="1" colspan="1">It may be safe not to administer postexposure prophylaxis in healthy individuals re-exposed to rabies within 3&#x000a0;months of pre-exposure or previous postexposure prophylaxis</td></tr></tbody></table><table-wrap-foot><p>PVRV: purified Vero cell rabies vaccine.</p><p><sup>a</sup> This study did not follow up study participants 1&#x000a0;year after pre-exposure prophylaxis or simulate responses to postexposure prophylaxis.</p></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Several studies demonstrated that pre-exposure rabies prophylaxis was safe and immunogenic in children and could be co-administered with other childhood vaccines.<xref rid="R21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="R22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="R27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="R32" ref-type="bibr"><sup>32</sup></xref><sup>,</sup><xref rid="R34" ref-type="bibr"><sup>34</sup></xref><sup>&#x02013;</sup><xref rid="R37" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="R40" ref-type="bibr"><sup>40</sup></xref> In addition, it could be given with the Japanese encephalitis vaccine in both adults and children. In most African countries pre-exposure rabies prophylaxis is unlikely to be included in the expanded programme on immunization because of competing priorities and because postexposure prophylaxis would still be required following suspected contact. Nevertheless, expert consultations advocate vaccination for people in remote, high-risk areas<xref rid="R6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="R19" ref-type="bibr"><sup>19</sup></xref><sup>,</sup><xref rid="R36" ref-type="bibr"><sup>36</sup></xref> and national pre-exposure prophylaxis programmes have been implemented in Peru and the Philippines.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="R7" ref-type="bibr"><sup>7</sup></xref> In Peru, the programme was successful in preventing child deaths due to bat rabies in high-risk areas, which demonstrates the value of targeted pre-exposure prophylaxis in places where controlling disease in the animal reservoir is challenging.<xref rid="R11" ref-type="bibr"><sup>11</sup></xref> Although it can be difficult for individuals to recall the date of pre-exposure prophylaxis, this does not undermine its usefulness for saving human lives in situations where exposure is uncertain or there is limited access to biologicals. Vaccination certificates are often treasured and kept safe and, in Peru, the identification and recording of vaccinated individuals has improved nationally.</p><p>Pre-exposure rabies prophylaxis is also associated with cost savings because fewer postexposure vaccinations and no rabies immunoglobulin are required following suspected exposure. However, the few studies that assessed costs suggest that community vaccination at current vaccine and delivery costs would not be cost-effective in most situations.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="R17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="R30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="R42" ref-type="bibr"><sup>42</sup></xref><sup>,</sup><xref rid="R43" ref-type="bibr"><sup>43</sup></xref> Preliminary studies on accelerated or revised regimens indicate that 1-week or even single-day regimens may be as effective as the recommended 3- to 4-week regimen: shorter treatment and fewer doses would make treatment simpler and less expensive.</p><p>The development of a more immunogenic rabies vaccine that provides life-long immunological memory with a single dose and that can be preserved at ambient temperatures, thereby eliminating the need for a cold chain, would make pre-exposure prophylaxis simpler and more cost-effective. The ideal vaccine would induce an antibody titre that remained above 0.5&#x000a0;IU/mL for decades and would protect people who fail to receive prompt booster immunization following exposure. In animal studies, attempts have been made to increase the current vaccine&#x02019;s immunogenicity using adjuvants,<xref rid="R44" ref-type="bibr"><sup>44</sup></xref><sup>,</sup><xref rid="R45" ref-type="bibr"><sup>45</sup></xref> genetic manipulation,<xref rid="R46" ref-type="bibr"><sup>46</sup></xref> adenovirus vectors derived from chimpanzee viruses<xref rid="R47" ref-type="bibr"><sup>47</sup></xref> and attenuated measles viruses,<xref rid="R48" ref-type="bibr"><sup>48</sup></xref><sup>,</sup><xref rid="R49" ref-type="bibr"><sup>49</sup></xref> which would enable combined early childhood immunization against both measles and rabies.</p><p>Although pre-exposure prophylaxis using currently available biologicals may not be cost-effective in general, we believe it could be beneficial in: (i)&#x000a0;remote communities where access to postexposure prophylaxis and rabies immunoglobulin is often delayed or nonexistent; (ii)&#x000a0;situations in which the risk of exposure is high and may go unrecognized, for example, in young children or people exposed occupationally, such as veterinarians; or (iii)&#x000a0;places where controlling rabies in the animal reservoir is difficult and the risk of human exposure is high, such as in the Amazon basin where bat rabies is endemic. It is important that staff involved in canine rabies control receive pre-exposure prophylaxis because of their higher risk of exposure. Currently, serological surveillance and booster vaccinations are recommended only for people at an occupational risk.<xref rid="R5" ref-type="bibr"><sup>5</sup></xref> Controlling canine rabies remains the cornerstone of preventing human rabies deaths. Pre-exposure prophylaxis should not distract from canine vaccination efforts, the provision of postexposure prophylaxis and education to raise local awareness of rabies. In high-risk areas, pre-exposure prophylaxis should be included in the expanded programme on immunization in children from 1&#x000a0;year of age,<xref rid="R5" ref-type="bibr"><sup>5</sup></xref> followed by a booster after 1&#x000a0;year. Vaccination should be documented with a certificate and any available medical records should be updated. Targeted, mass campaigns in remote, high-incidence areas should be considered to provide protection for both children and adults and travel recommendations should be provided for newcomers. Accelerated vaccination regimes and novel vaccines that provide life-long immunity with a single dose and are stable at ambient temperatures would make pre-exposure prophylaxis more cost-effective and easier to implement.</p></sec></body><back><ack><title>Acknowledgements</title><p>We thank staff at the National Zoonosis Strategy, Peruvian Ministry of Health, at the DIRESA Amazonas office and at the National Rabies Prevention and Control Program of the Philippine Department of Health.</p></ack><fn-group><title>Competing interests:</title><fn fn-type="financial-disclosure"><p>None declared.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><string-name><surname>Hampson</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Coudeville</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Lembo</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Sambo</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kieffer</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Attlan</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>; <collab>Global Alliance for Rabies Control Partners for Rabies Prevention</collab>. <article-title>Estimating the global burden of endemic canine rabies.</article-title>
<source>PLoS Negl Trop Dis</source>. <year>2015</year>
<month>4</month>;<volume>9</volume>(<issue>4</issue>):<fpage>e0003709</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0003709</pub-id><pub-id pub-id-type="pmid">25881058</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><string-name><surname>Knobel</surname>
<given-names>DL</given-names></string-name>, <string-name><surname>Cleaveland</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Coleman</surname>
<given-names>PG</given-names></string-name>, <string-name><surname>F&#x000e8;vre</surname>
<given-names>EM</given-names></string-name>, <string-name><surname>Meltzer</surname>
<given-names>MI</given-names></string-name>, <string-name><surname>Miranda</surname>
<given-names>ME</given-names></string-name>, <etal>et al.</etal>
<article-title>Re-evaluating the burden of rabies in Africa and Asia.</article-title>
<source>Bull World Health Organ</source>. <year>2005</year>
<month>5</month>;<volume>83</volume>(<issue>5</issue>):<fpage>360</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">15976877</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><string-name><surname>Crowcroft</surname>
<given-names>NS</given-names></string-name>, <string-name><surname>Thampi</surname>
<given-names>N</given-names></string-name>. <article-title>The prevention and management of rabies.</article-title>
<source>BMJ</source>. <year>2015;</year><volume>350</volume>:<fpage>g7827</fpage>.<pub-id pub-id-type="pmid">25589091</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><string-name><surname>Dodet</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Durrheim</surname>
<given-names>DN</given-names></string-name>, <string-name><surname>Rees</surname>
<given-names>H</given-names></string-name>. <article-title>Rabies: underused vaccines, unnecessary deaths.</article-title>
<source>Vaccine</source>. <year>2014</year>
<month>4</month>
<day>11</day>;<volume>32</volume>(<issue>18</issue>):<fpage>2017</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2013.12.031</pub-id><pub-id pub-id-type="pmid">24434045</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><article-title>Rabies vaccines: WHO position paper</article-title>. <source>Wkly Epidemiol Rec</source>. <year>2010</year>
<month>8</month>
<day>6</day>;<volume>85</volume>(<issue>32</issue>):<fpage>309</fpage>&#x02013;<lpage>20</lpage>.</mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="book"><source>Estrategia nacional de zoonosis-MINSA. Informe 37-2015. Resultados plan de vacunaci&#x000f3;n antirr&#x000e1;bica de pre-exposici&#x000f3;n en comunidades en riesgo de rabia de la Region Amazonas: Per&#x000fa; 2011&#x02013;2014.</source>
<publisher-loc>Lima</publisher-loc>: <publisher-name>Ministerio de Salud del Per&#x000fa;</publisher-name>; <year>2014</year>. <comment>Spanish.</comment><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.02.093</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><string-name><surname>Dodet</surname>
<given-names>B</given-names></string-name>; <collab>Asian Rabies Expert Bureau (AREB)</collab>. <article-title>Report of the sixth AREB meeting, Manila, The Philippines, 10&#x02013;12 November 2009.</article-title>
<source>Vaccine</source>. <year>2010</year>
<month>4</month>
<day>26</day>;<volume>28</volume>(<issue>19</issue>):<fpage>3265</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2010.02.093</pub-id><pub-id pub-id-type="pmid">20211220</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><string-name><surname>Moher</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Liberati</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Tetzlaff</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Altman</surname>
<given-names>DG</given-names></string-name>; <collab>PRISMA Group</collab>. <article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.</article-title>
<source>Ann Intern Med</source>. <year>2009</year>
<month>8</month>
<day>18</day>;<volume>151</volume>(<issue>4</issue>):<fpage>264</fpage>&#x02013;<lpage>9, W64</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-151-4-200908180-00135</pub-id><pub-id pub-id-type="pmid">19622511</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><string-name><surname>Gilbert</surname>
<given-names>AT</given-names></string-name>, <string-name><surname>Petersen</surname>
<given-names>BW</given-names></string-name>, <string-name><surname>Recuenco</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Niezgoda</surname>
<given-names>M</given-names></string-name>, <string-name><surname>G&#x000f3;mez</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Laguna-Torres</surname>
<given-names>VA</given-names></string-name>, <etal>et al.</etal>
<article-title>Evidence of rabies virus exposure among humans in the Peruvian Amazon.</article-title>
<source>Am J Trop Med Hyg</source>. <year>2012</year>
<month>8</month>;<volume>87</volume>(<issue>2</issue>):<fpage>206</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.2012.11-0689</pub-id><pub-id pub-id-type="pmid">22855749</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><string-name><surname>Schneider</surname>
<given-names>MC</given-names></string-name>, <string-name><surname>Aron</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Santos-Burgoa</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Uieda</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Ruiz-Velazco</surname>
<given-names>S</given-names></string-name>. <article-title>Common vampire bat attacks on humans in a village of the Amazon region of Brazil.</article-title>
<source>Cad Saude Publica</source>. <year>2001</year>
<season>Nov-Dec</season>;<volume>17</volume>(<issue>6</issue>):<fpage>1531</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1590/S0102-311X2001000600038</pub-id><pub-id pub-id-type="pmid">11784915</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><string-name><surname>Streicker</surname>
<given-names>DG</given-names></string-name>, <string-name><surname>Recuenco</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Valderrama</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Gomez Benavides</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Vargas</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Pacheco</surname>
<given-names>V</given-names></string-name>, <etal>et al.</etal>
<article-title>Ecological and anthropogenic drivers of rabies exposure in vampire bats: implications for transmission and control.</article-title>
<source>Proc Biol Sci</source>. <year>2012</year>
<month>9</month>
<day>7</day>;<volume>279</volume>(<issue>1742</issue>):<fpage>3384</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1098/rspb.2012.0538</pub-id><pub-id pub-id-type="pmid">22696521</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="web">National rabies prevention and control program. Manual of operations (2012). Manila: Department of Health, Philippines; 2012. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.doh.gov.ph/sites/default/files/publications/FINALMOP6.4.13WORDRADMay30.pdf">http://www.doh.gov.ph/sites/default/files/publications/FINALMOP6.4.13WORDRADMay30.pdf</ext-link> [cited 2016 Nov 18].</mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><string-name><surname>Aikimbayev</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Briggs</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Coltan</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Dodet</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Farahtaj</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Imnadze</surname>
<given-names>P</given-names></string-name>, <etal>et al.</etal>
<article-title>Fighting rabies in Eastern Europe, the Middle East and Central Asia&#x02013;experts call for a regional initiative for rabies elimination.</article-title>
<source>Zoonoses Public Health</source>. <year>2014</year>
<month>5</month>;<volume>61</volume>(<issue>3</issue>):<fpage>219</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1111/zph.12060</pub-id><pub-id pub-id-type="pmid">23782901</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><string-name><surname>Banga</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Guss</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Banga</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Rosenman</surname>
<given-names>KD</given-names></string-name>. <article-title>Incidence and variables associated with inadequate antibody titers after pre-exposure rabies vaccination among veterinary medical students.</article-title>
<source>Vaccine</source>. <year>2014</year>
<month>2</month>
<day>12</day>;<volume>32</volume>(<issue>8</issue>):<fpage>979</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2013.12.019</pub-id><pub-id pub-id-type="pmid">24394442</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><string-name><surname>Brown</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Fooks</surname>
<given-names>AR</given-names></string-name>, <string-name><surname>Schweiger</surname>
<given-names>M</given-names></string-name>. <article-title>Using intradermal rabies vaccine to boost immunity in people with low rabies antibody levels.</article-title>
<source>Adv Prev Med</source>. <year>2011</year>;<volume>2011</volume>:<fpage>601789</fpage>. <pub-id pub-id-type="doi">10.4061/2011/601789</pub-id><pub-id pub-id-type="pmid">21991440</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><string-name><surname>Brown</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Featherstone</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Fooks</surname>
<given-names>AR</given-names></string-name>, <string-name><surname>Gettner</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Lloyd</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Schweiger</surname>
<given-names>M</given-names></string-name>. <article-title>Intradermal pre-exposure rabies vaccine elicits long lasting immunity.</article-title>
<source>Vaccine</source>. <year>2008</year>
<month>7</month>
<day>23</day>;<volume>26</volume>(<issue>31</issue>):<fpage>3909</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2008.04.081</pub-id><pub-id pub-id-type="pmid">18547689</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><string-name><surname>Chulasugandha</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Khawplod</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Havanond</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Wilde</surname>
<given-names>H</given-names></string-name>. <article-title>Cost comparison of rabies pre-exposure vaccination with post-exposure treatment in Thai children.</article-title>
<source>Vaccine</source>. <year>2006</year>
<month>2</month>
<day>27</day>;<volume>24</volume>(<issue>9</issue>):<fpage>1478</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2005.03.059</pub-id><pub-id pub-id-type="pmid">16221511</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><string-name><surname>Cunha</surname>
<given-names>RS</given-names></string-name>, <string-name><surname>Silva</surname>
<given-names>A de C</given-names></string-name>, <string-name><surname>Batista</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Chaves</surname>
<given-names>LB</given-names></string-name>, <string-name><surname>Barata</surname>
<given-names>RB</given-names></string-name>. <article-title>Equivalence between pre-exposure schemes for human rabies and evaluation of the need for serological monitoring.</article-title>
<source>Rev Saude Publica</source>. <year>2010</year>
<month>6</month>;<volume>44</volume>(<issue>3</issue>):<fpage>548</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1590/S0034-89102010005000005</pub-id><pub-id pub-id-type="pmid">20464263</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><string-name><surname>Dodet</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Asian Rabies Expert</surname>
<given-names>B</given-names></string-name>; <collab>Asian Rabies Expert Bureau (AREB)</collab>. <article-title>Report of the Fifth AREB Meeting Ho Chi Minh City, Vietnam, 17&#x02013;20 November 2008.</article-title>
<source>Vaccine</source>. <year>2009</year>
<month>4</month>
<day>21</day>;<volume>27</volume>(<issue>18</issue>):<fpage>2403</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2009.02.012</pub-id><pub-id pub-id-type="pmid">19368779</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><string-name><surname>Jelinek</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Cramer</surname>
<given-names>JP</given-names></string-name>, <string-name><surname>Dieckmann</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Hatz</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Paulke-Korinek</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Alberer</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>Evaluation of rabies immunogenicity and tolerability following a purified chick embryo cell rabies vaccine administered concomitantly with a Japanese encephalitis vaccine.</article-title>
<source>Travel Med Infect Dis</source>. <year>2015</year>
<season>May-Jun</season>;<volume>13</volume>(<issue>3</issue>):<fpage>241</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.tmaid.2015.05.008</pub-id><pub-id pub-id-type="pmid">26005163</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><string-name><surname>Kamoltham</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Thinyounyong</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Khawplod</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Phraisuwan</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Phongchamnaphai</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Anders</surname>
<given-names>G</given-names></string-name>, <etal>et al.</etal>
<article-title>Immunogenicity of simulated PCECV postexposure booster doses 1, 3, and 5 years after 2-dose and 3-dose primary rabies vaccination in schoolchildren.</article-title>
<source>Adv Prev Med</source>. <year>2011</year>;<volume>2011</volume>:<fpage>403201</fpage>. <pub-id pub-id-type="doi">10.4061/2011/403201</pub-id><pub-id pub-id-type="pmid">21991438</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><string-name><surname>Kamoltham</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Thinyounyong</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Phongchamnaphai</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Phraisuwan</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Khawplod</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Banzhoff</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal>
<article-title>Pre-exposure rabies vaccination using purified chick embryo cell rabies vaccine intradermally is immunogenic and safe.</article-title>
<source>J Pediatr</source>. <year>2007</year>
<month>8</month>;<volume>151</volume>(<issue>2</issue>):<fpage>173</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpeds.2007.02.044</pub-id><pub-id pub-id-type="pmid">17643772</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><string-name><surname>Khawplod</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Wilde</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Sriaroon</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Chomchey</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Kamolthum</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Sitprija</surname>
<given-names>V</given-names></string-name>. <article-title>One or three intradermal injections within one week for rabies pre-exposure immunization.</article-title>
<source>Dev Biol (Basel)</source>. <year>2008</year>;<volume>131</volume>:<fpage>393</fpage>&#x02013;<lpage>401</lpage>.<pub-id pub-id-type="pmid">18634501</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><string-name><surname>Khawplod</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Jaijaroensup</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Sawangvaree</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Prakongsri</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Wilde</surname>
<given-names>H</given-names></string-name>. <article-title>One clinic visit for pre-exposure rabies vaccination (a preliminary one year study).</article-title>
<source>Vaccine</source>. <year>2012</year>
<month>4</month>
<day>19</day>;<volume>30</volume>(<issue>19</issue>):<fpage>2918</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2011.12.028</pub-id><pub-id pub-id-type="pmid">22178519</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><string-name><surname>Khawplod</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Wilde</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Benjavongkulchai</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Sriaroon</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Chomchey</surname>
<given-names>P</given-names></string-name>. <article-title>Immunogenicity study of abbreviated rabies preexposure vaccination schedules.</article-title>
<source>J Travel Med</source>. <year>2007</year>
<season>May-Jun</season>;<volume>14</volume>(<issue>3</issue>):<fpage>173</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1111/j.1708-8305.2007.00120.x</pub-id><pub-id pub-id-type="pmid">17437473</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><string-name><surname>Lang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Duong</surname>
<given-names>GH</given-names></string-name>, <string-name><surname>Nguyen</surname>
<given-names>VG</given-names></string-name>, <string-name><surname>Le</surname>
<given-names>TT</given-names></string-name>, <string-name><surname>Nguyen</surname>
<given-names>CV</given-names></string-name>, <string-name><surname>Kesmedjian</surname>
<given-names>V</given-names></string-name>, <etal>et al.</etal>
<article-title>Randomised feasibility trial of pre-exposure rabies vaccination with DTP-IPV in infants.</article-title>
<source>Lancet</source>. <year>1997</year>
<month>6</month>
<day>7</day>;<volume>349</volume>(<issue>9066</issue>):<fpage>1663</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(96)10085-4</pub-id><pub-id pub-id-type="pmid">9186385</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><string-name><surname>Lang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Feroldi</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Vien</surname>
<given-names>NC</given-names></string-name>. <article-title>Pre-exposure purified vero cell rabies vaccine and concomitant routine childhood vaccinations: 5-year post-vaccination follow-up study of an infant cohort in Vietnam.</article-title>
<source>J Trop Pediatr</source>. <year>2009</year>
<month>2</month>;<volume>55</volume>(<issue>1</issue>):<fpage>26</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1093/tropej/fmm100</pub-id><pub-id pub-id-type="pmid">18048461</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><string-name><surname>Lau</surname>
<given-names>CL</given-names></string-name>, <string-name><surname>Hohl</surname>
<given-names>N</given-names></string-name>. <article-title>Immunogenicity of a modified intradermal pre-exposure rabies vaccination schedule using a purified chick embryo cell vaccine: an observational study.</article-title>
<source>Travel Med Infect Dis</source>. <year>2013</year>
<season>Nov-Dec</season>;<volume>11</volume>(<issue>6</issue>):<fpage>427</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.tmaid.2013.09.006</pub-id><pub-id pub-id-type="pmid">24135254</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><string-name><surname>Lim</surname>
<given-names>PL</given-names></string-name>, <string-name><surname>Barkham</surname>
<given-names>TM</given-names></string-name>. <article-title>Serologic response to rabies pre-exposure vaccination in persons with potential occupational exposure in Singapore.</article-title>
<source>Int J Infect Dis</source>. <year>2010</year>
<month>6</month>;<volume>14</volume>(<issue>6</issue>):<fpage>e511</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2009.08.008</pub-id><pub-id pub-id-type="pmid">20018545</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><string-name><surname>Liu</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Ertl</surname>
<given-names>HC</given-names></string-name>. <article-title>Preventative childhood vaccination to rabies.</article-title>
<source>Expert Opin Biol Ther</source>. <year>2012</year>
<month>8</month>;<volume>12</volume>(<issue>8</issue>):<fpage>1067</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1517/14712598.2012.691162</pub-id><pub-id pub-id-type="pmid">22724389</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><string-name><surname>Lumbiganon</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Chaiprasithikul</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Sookpranee</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Paholpak</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Wasi</surname>
<given-names>C</given-names></string-name>. <article-title>Pre-exposure vaccination with purified chick embryo cell rabies vaccines in children.</article-title>
<source>Asian Pac J Allergy Immunol</source>. <year>1989</year>
<month>12</month>;<volume>7</volume>(<issue>2</issue>):<fpage>99</fpage>&#x02013;<lpage>101</lpage>.<pub-id pub-id-type="pmid">2624670</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><string-name><surname>Malerczyk</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Vakil</surname>
<given-names>HB</given-names></string-name>, <string-name><surname>Bender</surname>
<given-names>W</given-names></string-name>. <article-title>Rabies pre-exposure vaccination of children with purified chick embryo cell vaccine (PCECV).</article-title>
<source>Hum Vaccin Immunother</source>. <year>2013</year>
<month>7</month>;<volume>9</volume>(<issue>7</issue>):<fpage>1454</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.4161/hv.24502</pub-id><pub-id pub-id-type="pmid">23571224</pub-id></mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><string-name><surname>Mills</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Lau</surname>
<given-names>CL</given-names></string-name>, <string-name><surname>Fearnley</surname>
<given-names>EJ</given-names></string-name>, <string-name><surname>Weinstein</surname>
<given-names>P</given-names></string-name>. <article-title>The immunogenicity of a modified intradermal pre-exposure rabies vaccination schedule&#x02013;a case series of 420 travelers.</article-title>
<source>J Travel Med</source>. <year>2011</year>
<season>Sep-Oct</season>;<volume>18</volume>(<issue>5</issue>):<fpage>327</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1111/j.1708-8305.2011.00540.x</pub-id><pub-id pub-id-type="pmid">21896096</pub-id></mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><string-name><surname>Pengsaa</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Limkittikul</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Sabchareon</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Ariyasriwatana</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Chanthavanich</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Attanath</surname>
<given-names>P</given-names></string-name>, <etal>et al.</etal>
<article-title>A three-year clinical study on immunogenicity, safety, and booster response of purified chick embryo cell rabies vaccine administered intramuscularly or intradermally to 12- to 18-month-old Thai children, concomitantly with Japanese encephalitis vaccine.</article-title>
<source>Pediatr Infect Dis J</source>. <year>2009</year>
<month>4</month>;<volume>28</volume>(<issue>4</issue>):<fpage>335</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1097/INF.0b013e3181906351</pub-id><pub-id pub-id-type="pmid">19333080</pub-id></mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><string-name><surname>Ravish</surname>
<given-names>HS</given-names></string-name>, <string-name><surname>Srikanth</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Ashwath Narayana</surname>
<given-names>DH</given-names></string-name>, <string-name><surname>Annadani</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Vijayashankar</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Undi</surname>
<given-names>M</given-names></string-name>. <article-title>Pre-exposure prophylaxis against rabies in children: safety of purified chick embryo cell rabies vaccine (Vaxirab N) when administered by intradermal route.</article-title>
<source>Hum Vaccin Immunother</source>. <year>2013</year>
<month>9</month>;<volume>9</volume>(<issue>9</issue>):<fpage>1910</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.4161/hv.25203</pub-id><pub-id pub-id-type="pmid">23787889</pub-id></mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="journal"><string-name><surname>Shanbag</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Shah</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Kulkarni</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Juvekar</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Madhusudana</surname>
<given-names>SN</given-names></string-name>, <string-name><surname>Vakil</surname>
<given-names>HB</given-names></string-name>, <etal>et al.</etal>
<article-title>Protecting Indian schoolchildren against rabies: pre-exposure vaccination with purified chick embryo cell vaccine (PCECV) or purified verocell rabies vaccine (PVRV).</article-title>
<source>Hum Vaccin</source>. <year>2008</year>
<season>Sep-Oct</season>;<volume>4</volume>(<issue>5</issue>):<fpage>365</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.4161/hv.4.5.5987</pub-id><pub-id pub-id-type="pmid">18398307</pub-id></mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="journal"><string-name><surname>Strady</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Andreoletti</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Baumard</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Servettaz</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Jaussaud</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Strady</surname>
<given-names>A</given-names></string-name>. <article-title>Immunogenicity and booster efficacy of pre-exposure rabies vaccination.</article-title>
<source>Trans R Soc Trop Med Hyg</source>. <year>2009</year>
<month>11</month>;<volume>103</volume>(<issue>11</issue>):<fpage>1159</fpage>&#x02013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.trstmh.2009.03.007</pub-id><pub-id pub-id-type="pmid">19359026</pub-id></mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal"><string-name><surname>Sudarshan</surname>
<given-names>MK</given-names></string-name>, <string-name><surname>Ravish</surname>
<given-names>HS</given-names></string-name>, <string-name><surname>Narayana</surname>
<given-names>DHA</given-names></string-name>. <article-title>Time interval for booster vaccination following re-exposure to rabies in previously vaccinated subjects.</article-title>
<source>Asian Biomed</source>. <year>2011</year>;<volume>5</volume>(<issue>5</issue>):<fpage>589</fpage>&#x02013;<lpage>93</lpage>.</mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal"><string-name><surname>Vashishtha</surname>
<given-names>VM</given-names></string-name>, <string-name><surname>Choudhury</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Kalra</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Bose</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Thacker</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Yewale</surname>
<given-names>VN</given-names></string-name>, <etal>et al.</etal>; <collab>Indian Academy of Pediatrics</collab>. <article-title>Indian Academy of Pediatrics (IAP) recommended immunization schedule for children aged 0 through 18 years&#x02013;India, 2014 and updates on immunization.</article-title>
<source>Indian Pediatr</source>. <year>2014</year>
<month>10</month>;<volume>51</volume>(<issue>10</issue>):<fpage>785</fpage>&#x02013;<lpage>800</lpage>. <pub-id pub-id-type="doi">10.1007/s13312-014-0504-y</pub-id><pub-id pub-id-type="pmid">25362009</pub-id></mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="journal"><string-name><surname>Vien</surname>
<given-names>NC</given-names></string-name>, <string-name><surname>Feroldi</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Lang</surname>
<given-names>J</given-names></string-name>. <article-title>Long-term anti-rabies antibody persistence following intramuscular or low-dose intradermal vaccination of young Vietnamese children.</article-title>
<source>Trans R Soc Trop Med Hyg</source>. <year>2008</year>
<month>3</month>;<volume>102</volume>(<issue>3</issue>):<fpage>294</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.trstmh.2007.11.010</pub-id><pub-id pub-id-type="pmid">18191971</pub-id></mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="journal"><string-name><surname>Wongsaroj</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Udomchaisakul</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Tepsumethanon</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Khawplod</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Tantawichien</surname>
<given-names>T</given-names></string-name>. <article-title>Rabies neutralizing antibody after 2 intradermal doses on days 0 and 21 for pre-exposure prophylaxis.</article-title>
<source>Vaccine</source>. <year>2013</year>
<month>3</month>
<day>25</day>;<volume>31</volume>(<issue>13</issue>):<fpage>1748</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2013.01.035</pub-id><pub-id pub-id-type="pmid">23370149</pub-id></mixed-citation></ref><ref id="R42"><label>42</label><mixed-citation publication-type="journal"><string-name><surname>Bernard</surname>
<given-names>KW</given-names></string-name>, <string-name><surname>Fishbein</surname>
<given-names>DB</given-names></string-name>. <article-title>Pre-exposure rabies prophylaxis for travellers: are the benefits worth the cost?</article-title>
<source>Vaccine</source>. <year>1991</year>
<month>11</month>;<volume>9</volume>(<issue>11</issue>):<fpage>833</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/0264-410X(91)90221-Q</pub-id><pub-id pub-id-type="pmid">1759505</pub-id></mixed-citation></ref><ref id="R43"><label>43</label><mixed-citation publication-type="journal"><string-name><surname>Strady</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Hung Nguyen</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Jaussaud</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Lang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Lienard</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Strady</surname>
<given-names>A</given-names></string-name>. <article-title>Pre-exposure rabies vaccination: strategies and cost-minimization study.</article-title>
<source>Vaccine</source>. <year>2001</year>
<month>1</month>
<day>8</day>;<volume>19</volume>(<issue>11-12</issue>):<fpage>1416</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/S0264-410X(00)00368-6</pub-id><pub-id pub-id-type="pmid">11163664</pub-id></mixed-citation></ref><ref id="R44"><label>44</label><mixed-citation publication-type="journal"><string-name><surname>DiStefano</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Antonello</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Bett</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Medi</surname>
<given-names>MB</given-names></string-name>, <string-name><surname>Casimiro</surname>
<given-names>DR</given-names></string-name>, <string-name><surname>ter Meulen</surname>
<given-names>J</given-names></string-name>. <article-title>Immunogenicity of a reduced-dose whole killed rabies vaccine is significantly enhanced by ISCOMATRIX&#x02122; adjuvant, Merck amorphous aluminum hydroxylphosphate sulfate (MAA) or a synthetic TLR9 agonist in rhesus macaques.</article-title>
<source>Vaccine</source>. <year>2013</year>
<month>10</month>
<day>1</day>;<volume>31</volume>(<issue>42</issue>):<fpage>4888</fpage>&#x02013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2013.07.034</pub-id><pub-id pub-id-type="pmid">23941913</pub-id></mixed-citation></ref><ref id="R45"><label>45</label><mixed-citation publication-type="journal"><string-name><surname>Hu</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Zhu</surname>
<given-names>N</given-names></string-name>. <article-title>Enhancement of humoral and cellular immune responses by monophosphoryl lipid A (MPLA) as an adjuvant to the rabies vaccine in BALB/c mice.</article-title>
<source>Immunobiology</source>. <year>2013</year>
<month>12</month>;<volume>218</volume>(<issue>12</issue>):<fpage>1524</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.imbio.2013.05.006</pub-id><pub-id pub-id-type="pmid">23816301</pub-id></mixed-citation></ref><ref id="R46"><label>46</label><mixed-citation publication-type="journal"><string-name><surname>Cenna</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Hunter</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Tan</surname>
<given-names>GS</given-names></string-name>, <string-name><surname>Papaneri</surname>
<given-names>AB</given-names></string-name>, <string-name><surname>Ribka</surname>
<given-names>EP</given-names></string-name>, <string-name><surname>Schnell</surname>
<given-names>MJ</given-names></string-name>, <etal>et al.</etal>
<article-title>Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates.</article-title>
<source>J Infect Dis</source>. <year>2009</year>
<month>10</month>
<day>15</day>;<volume>200</volume>(<issue>8</issue>):<fpage>1251</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1086/605949</pub-id><pub-id pub-id-type="pmid">19764884</pub-id></mixed-citation></ref><ref id="R47"><label>47</label><mixed-citation publication-type="journal"><string-name><surname>Xiang</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Cun</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Ellenberg</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Switzer</surname>
<given-names>WM</given-names></string-name>, <etal>et al.</etal>
<article-title>Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa.</article-title>
<source>Emerg Infect Dis</source>. <year>2006</year>
<month>10</month>;<volume>12</volume>(<issue>10</issue>):<fpage>1596</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.3201/eid1210.060078</pub-id><pub-id pub-id-type="pmid">17176582</pub-id></mixed-citation></ref><ref id="R48"><label>48</label><mixed-citation publication-type="journal"><string-name><surname>Ramsauer</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Schwameis</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Firbas</surname>
<given-names>C</given-names></string-name>, <string-name><surname>M&#x000fc;llner</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Putnak</surname>
<given-names>RJ</given-names></string-name>, <string-name><surname>Thomas</surname>
<given-names>SJ</given-names></string-name>, <etal>et al.</etal>
<article-title>Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.</article-title>
<source>Lancet Infect Dis</source>. <year>2015</year>
<month>5</month>;<volume>15</volume>(<issue>5</issue>):<fpage>519</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(15)70043-5</pub-id><pub-id pub-id-type="pmid">25739878</pub-id></mixed-citation></ref><ref id="R49"><label>49</label><mixed-citation publication-type="journal"><string-name><surname>Rennick</surname>
<given-names>LJ</given-names></string-name>, <string-name><surname>de Vries</surname>
<given-names>RD</given-names></string-name>, <string-name><surname>Carsillo</surname>
<given-names>TJ</given-names></string-name>, <string-name><surname>Lemon</surname>
<given-names>K</given-names></string-name>, <string-name><surname>van Amerongen</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Ludlow</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>Live-attenuated measles virus vaccine targets dendritic cells and macrophages in muscle of nonhuman primates.</article-title>
<source>J Virol</source>. <year>2015</year>
<month>2</month>;<volume>89</volume>(<issue>4</issue>):<fpage>2192</fpage>&#x02013;<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02924-14</pub-id><pub-id pub-id-type="pmid">25473055</pub-id></mixed-citation></ref></ref-list></back></article>